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Abstract
External beam radiotherapy (RT) is the primary treatment modality for patients with inoper-
able lung tumours. Respiration-induced motion and related intra-/interfractional variations
present a series of limitations to the success of existing conventional treatment modalities
for lung cancer. Subsequently, to minimise the effects of respiration different management
techniques have been proposed and are available. Respiratory gated radiotherapy (RGRT)
holds promise to improve dose conformity, reduce the normal tissue control probability while
increasing the tumour control probability. Its effectiveness depends on precise tumour lo-
calisation and targeting during dose delivery. In this thesis, the suitability of RGRT for the
compensation of breathing induced motion was investigated by means of phantom studies
and film dosimetry. Both regular and irregular trajectories were simulated during gated
dose delivery and their effects on dose distributions analysed. Respiration-induced motion
led to dose blurring and hence to less conformal dose distributions, which resulted overall in
underdose of the treatment planning volume and an overdose of healthy surrounding tissue.
Compared to non-gated dose delivery, RGRT improved dose conformity by enabling steeper
dose gradients, resulting in an increased sparing of healthy tissue, at the expenses of increased
delivery times. In the presence of irregular motion paths the dosimetric advantages of RGRT
were observed to decrease. In the absence of a clinical tool for treatment verification such
irregularities may pass unnoticeable and may lead to poor treatment outcomes.
Investigations of the suitability of a software tool for tracking lung tumours in portal im-
ages during RGRT demonstrated that it is possible to determine and track tumour motion
during gated treatment. Both the residual tumour motion inside the gating window as well
as the probability density function were used as measures to quantify tumour position and
variability. Tracking information was sufficient to quantify residual motion and variability.
Baseline drifts as well as sudden fluctuations in tumour positions were detected and quan-
tified, which led to considerable variations in residual motion which in turn may result in
marginal miss. Although this was a retrospective analysis of motion data, the tool showed
a great potential for verification of the tumour position during RGRT and may possibly be
useful for adaptation of the gating window.
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Chapter 1
Introduction
1.1 Background
Lung cancer has long been recognised as one of the major causes of cancer-related deaths
worldwide [1], ranking first and second in terms of incidences for males and females in 2008
[2]. Based on the World Health Organisation (WHO) histologic lung cancer classification, the
four major types of lung cancer are squamous cell carcinoma, adenocarcinoma, non-small cell
lung cancer (NSCLC), and small-cell undifferentiated carcinoma [1], with NSCLC accounting
for most of the lung cancer cases reported. For patients suffering from NSCLC, tumour stage
is the most important prognosis factor, which determines treatment modality. Although,
surgery is the primary treatment choice for patients suffering from stage I-II tumours as
well as some selective cases of stage III tumours, only the minority of them (about 20%)
are suitable to undergo surgery due to co-morbid conditions, such as compromised lung
function, bleeding tendency [3]. External-beam radiotherapy (RT), either alone for patients
who present with stage I/II or combined with concurrent chemotherapy, in case of locally
advanced (stage III) disease, is the treatment of choice for patients who are inoperable due to
medical co-morbidities [3]. However, despite the increased efforts to control or eradicate the
disease, the treatment of pulmonary tumours is among one of the most technically challenging
procedures in radiation oncology [4]. This has been reflected in the limited improvements
in survival rates observed in the last years, with one Radiation Therapy Oncology Group
(RTOG) report indicating the 5-year survival rate between 13% - 16% [5].
Since the beginnings of the application of x-rays in radiation therapy, several attempts
have been made to concentrate the dose distributions within specified treatment volumes
[6]. Initially, rectangular cross-fired fields of uniform fluences were used to treat tumours
[7], which delivered unwanted doses to surrounding structures. Then over the following
years, the need to concentrate the treatment radiation fields within the target volumes was
better understood, which led to the development and combined implementation of a se-
ries of mechanical devices and treatment planning techniques to fulfill this objective [4, 8].
Subsequently, conformal radiotherapy (CFRT) was developed and then three dimensional
conformal radiotherapy (3D-CRT). An important step in 3D-CRT was the use of metal
blocks, made from low melting points alloy, to generate irregularly shaped irradiations field
[9]. Although this improved dose conformity, it turned out to be time-consuming and ex-
pensive as the blocks had to be customized based on patient-/beam-specific characteristics.
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Alternatively, a great progress in conformal radiotherapy was achieved with the development
of multileaf collimators (MLCs), which offered dose conformity similar or equivalent to con-
formal blocks. With MLCs more convenient irregular field shapes could be created and soon
became a standard feature implemented into most clinical linear accelerators.
3D-CRT is an extension of CFRT, which has allowed the inclusion of 3D anatomic in-
formation into the process of treatment planning [9]. This enabled the design of dose dis-
tributions that can be shaped to conform to target volumes by the use of forward planning
process, multimodality imaging and sophisticated delivery techniques [3, 9]. The overall goal
was to conform the dose distributions as close as possible to target volume in terms of ade-
quate dose to the tumour and minimum possible dose to the normal tissue. This objective
involves both physical and biological rationales, such as maximising tumour control prob-
ability (TCP) and minimising normal tissue complications probability (NTCP), to achieve
the desired clinical result.
In the last decades, a more advanced form of (CFRT), known as intensity-modulated
radiation therapy (IMRT) [8], has emerged as the result of the improved physical basis
of radiation therapy [6]. IMRT combines geometrical and fluence shaping to the clinical
requirements, allowing photon fields fluence modulation pixel-by-pixel [8]. This way, a high
dose distribution can be tailored to concave target volumes with greater sparing of healthy
tissue. Intensity-modulated beams are generated via inverse planning techniques [6], which
are the opposite to existing trial-and-error forward planning, in which the planner start out
by specifying the prescribed dose and algorithms seeks to arrive at the “optimum plan”,
consisting of the most acceptable compromised beam segments closest to optimum. The
beginnings of IMRT can be attributed to works by Brahme in early 1980s [8]. In 1982,
Brahme put into effect his newly introduced planning technique, which reversed the order of
existent trial-and-error forward method used at that times [8]. Brahme demonstrated how to
create a circular uniform dose D, with outer radius Rout enclosing a smaller concentric circle
of radius rin with zero dose by a rotation technique [8]. Figure 1.1 shows how by blocking the
inner central region (OARs) and then rotating the beam, a non-uniform dose distribution is
formed in surrouding outer circle with almost zero fluence from origin out to rin [6].
Figure 1.1: Brahme’s 1982 rotation technique with central blocking used to generate an
inhomogeneous dose distribution in the target, with zero fluence around a critical struc-
ture.(Modified figure taken from Image-guide IMRT [4])
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The success of lung cancer RT relies on accurate imaging (tumour definition/localisation),
treatment planning and delivery (tumour targeting) [10, 11]. However, because of the
fractionated-nature of RT and the associated treatment workflow [9], organ movement due
to different physiological processes results in a series of inherent geometrical uncertainties,
which may lead to poor outcomes of RT. Respiration has been recognised as a major lim-
iting factor to the success of RT for lung tumours, inducing uncertainties during imaging,
planning, and delivery. Normally, all such uncertainties in combination with intrafractional
tumour motion are compensated with large margins [12, 13, 14]. This, inevitably results in
exposure of surrounding healthy lung tissue and other organs-at-risk (OAR) to often unac-
ceptable levels of dose [11, 15, 16]. On the other hand, if healthy tissue toxicity is to be
kept below permissible levels, insufficient dose would be delivered to the tumour [17, 18].
Furthermore, there is evidence from dose-escalation studies, which have reported improved
local control and survival rates when higher doses compared to those of conventional frac-
tionated (60 - 66Gy in 1.8 or 2Gy/fractions) are used [19, 20], although these gains may be
compromised by the effects of respiration. This indicates the inability of existing modalities
and treatment protocols to control the disease [3, 17, 21] and the need for improvement of
local control.
Radiation therapy remains the main treatment modality for inoperable non-small cell
lung cancer despite some progress with the use of other treatment modalities such as surgery
and chemotherapy. Clinical studies have reported improved local controls and survival in pa-
tients with early-stage non-small cell lung cancer (NSCLC) treated with 3D-CRT, compared
to conventional 2D RT [22]. On the other hand, the use of IMRT to treat tumours in the
lung has largely been delayed due to concerns with the low dose tolerance of lung tissue, as
well as organ motion due to physiological processes, namely respiration, and other changes
in anatomy during course of treatment [4]. Although IMRT may be effective in minimising
NTCP while maximising TCP, its sharper fall-off of dose and conformity requires high level
of precision in tumour targeting during dose delivery [3, 9]. Therefore, it has been suggested
that if IMRT is to be more effective in treating NSCLC, the integration of other motion man-
agement technologies with IMRT, such as respiratory gating and tumour tracking, should
be explored [3, 4].
1.2 Motivation and Thesis Outline
The unpredictable nature of respiration and related uncertainties have presented a series
of challenges to existing modalities for the treatment of mobile tumour in the lung. Sub-
sequently, further improvements are still required to exploit their full potential. This has
prompted the development of motion management technologies, such as more representative
imaging systems and treatment techniques. Among existing techniques, respiratory gated
radiotherapy (RGRT) has gained increased popularity recently. RGRT has the potential
to reduce motion-induced irradiation of healthy lung tissue, which may in turn allow for
the reduction in treatment fields and ultimately dose escalation [23, 24, 25]. On the other
hand, many clinical institutions have developed gated treatment techniques that rely on the
monitoring of external surrogates to gate the delivery of treatment beams. Such technique is
advantageous provided that the correlation between the external surrogate and the tumour
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does not change in an unpredictable way throughout the treatment [26]. However, intra-
/interfractional variations in internal tumour mobility as well as breathing patterns have
been reported [27, 28], which may be the source of uncertainty. This in turn has caused
much ongoing debate about how well the monitoring of the external surrogate can predict
the internal tumour location. Therefore, it has been suggested that RGRT requires a veri-
fication system to ensure that the treatment scenario mimics the scenario observed during
treatment planning [29, 30]. It is hypothesized that tumour tracking can play an important
role to maximise the potential benefits of RGRT. This provided the impetus for this research.
In this work, the capabilities of a commercially available gating system were first tested
to investigate its suitability for the compensation of respiration induced motion. The main
objective was to simulate the effects of possible irregularities in tumour motion, which are
observed in real treatment procedures, on the system’s performance. In addition to this,
for the first time the suitability and potential of a clinical tool, denoted PortalTrack, for
treatment verification and markerless tracking of lung tumours in respiratory gated RT was
investigated.
This thesis consists of 6 chapters. The first chapter introduces the role that radiotherapy
plays to treat mobile tumours in the lung. Chapter 2 gives a general background of the
challenges presented by respiration and introduces some of the motion management tech-
niques for its compensation. In Chapter 3, a respiratory gated study was conducted in
order to give a preliminary insight into gated beam delivery. Both regular and irregular
tumour trajectories were simulated and their effects on dose distributions assessed by means
of film dosimetry. In Chapter 4, the suitability and potential of a clinical tool, denoted
PortalTrack, for tumour position verification during gated RT was investigated. In Chap-
ter 5, the suitability of the approach presented in Chapter 4 is evaluated with a clinical
case study. Lastly, Chapter 6 concludes this thesis by summarising the main results and
pointing out future developments.
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Chapter 2
Respiration Management
Radiotherapy (RT) of tumours located in the thoracic and abdominal region is associated
with a series of complex geometrical uncertainties, such as setup errors, respiratory motion,
intra-/interfractional variation and anatomic changes due to treatment response, which can
act during treatment preparation and execution [10, 14, 18]. In the case of patients suffering
from tumours in the lungs, respiratory motion has been regarded as a major source of
uncertainties which degrades the accuracy of RT at all stages of the treatment workflow [18,
31]: imaging, treatment planning and delivery. Consequently, leading to poor locoregional
control and treatment outcome, which is correlated with poor survival rates [21].
To date, much research and development has been directed towards accounting for res-
piratory motion. With the advent of recent technological advances several treatment tech-
niques have been proposed and are available with the attempt to take into account the
limitations presented by respiration motion. This, has led to an improved identification,
quantification and integration of uncertainties into treatment workflow of external-beam RT
for lung carcinoma. In principle, a full characterization of all such deviations as well as their
respective integration into the planning process should facilitate the generation of optimal
treatment margins. In section 2.1 and 2.2 an analysis of tumour motion is given. This
is followed in section 2.3 by introducing some techniques for its management, and then in
section 2.4 by outlining some issues associated with their use.
2.1 Tumour Motion
Numerous studies have been directed towards assessing, characterising and quantifying the
magnitude of respiration induced tumour motion in lung tissue [13, 27, 32], as well as,
its dosimetric impact [33, 34, 35]. Understanding the behaviour of tumour motion may
potentially lead to the design of more representative and robust models of tumour movement
[27, 36], and ultimately its prediction [37], which will allow for its better integration into the
treatment workflow and adaptation, and thus, improving the accuracy and effectiveness of
RT for mobile tumours in the lung.
Besides cardiac, muscular and peristaltic activity, which have been also reported to con-
tribute to organ motion [18, 27], respiratory activity has been regarded as the major source
of motion for tumours in pulmonary region with motion amplitudes over 2 cm reported in
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the literature [13, 27]. Studies such as those conducted by Seppenwoolde et al. [27] and
Shirato et al. [32], where the investigators used fiducial markers implanted in or near the tu-
mour, which were imaged in 3D via stereoscopic diagnostic x-ray fluoroscopy, have indicated
that tumour motion in the superior-inferior (SI) direction is more pronounced compared to
motion in the anterior-posterior (AP) and left-to-right (LR) directions, as shown in figure
2.1. This was observed, specially for tumours located in lower lobes and not attached to
rigid structures, compared to tumours located in other sites. Moreover, the exhalation phase
appeared to be more stable and last longer than the inhalation phase. Hysteresis in the tu-
mour trajectories, which is the different motion paths the tumour follows during inhalation
and exhalation, was also observed [27], suggesting that it may be due to the asymmetry in
the coupling two driving mechanisms, the diaphragm and intercostal muscles in the ribcage,
involved during respiration; or due to the lung’s dynamic properties so that due to the
elasticity of lung tissue, which can be further impaired by pulmonary diseases (emphysema,
fibrosis), the tumour motion lags behind (delayed) relative to the motion of chest wall or
diaphragm [27].
Figure 2.1: Position and shape of trajectories of 23 tumours on the coronal (left) and sagittal
(right) plane measured with implanted marker and real-time fluoroscopy. This illustration
shows that tumour motion is more pronounced in the superior-inferior direction for tumour
located in lower lobes compared to tumours in upper-lobes. (Figure taken from Sonke et al.
[38])
In addition to this, significant intra-/interfractional variations in tumours’ paths as well as
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in breathing level and intensity, are also described in the literature [26, 27, 28, 32, 34, 38, 39].
These studies have reported tumour motion variations in amplitude, period, mean (baseline
drifts) and in inhale/exhale (exhale/inhale fluctuations) position. Furthermore, the corre-
lation between the occurrence/magnitude of tumour motion and tumour size, location and
pulmonary function has been observed to be controversial among studies. These observations
have led to the conclusions that there are no general patterns of respiratory behaviour that
can be assumed prior to treatment, suggesting that tumour motion should be characterised
and assessed individually for each patient [18]. Therefore, because of the above-mentioned
variations in the tumour trajectories, with clinically observed variations, i.e., baseline drifts,
tumour motion can not be easily modelled by a simple function [34], such as in the case of
a popular model described in the work of Shirato et al. [27]:
S(t) = So − Acos2n(pit/T − φ) (2.1)
where So is the tumour position at exhalation, A the peak-to-peak motion amplitude,
T the period of breathing cycle and φ the starting phase. n is an integer, taking normally
values between 1-2, which makes the function model the fact that the tumour spends more
time at the exhale compared to the inhale position.
2.2 Respiration-induced Uncertainties
2.2.1 Systematic and Random Uncertainties
Geometric uncertainties induced by respiratory motion can be modeled as the combina-
tion of systematic and random components, which can take place intra-/interfractionally
[34, 38, 40]. The systematic component can be defined as errors that are introduced during
the preparation phase of treatment, i. e. imaging artifacts leading to erroneous target defini-
tion/and delineation due to the use of a non-time resolved CT, which will affect all fractions
throughout the treatment in the same way. The random component can be thought of as un-
certainties introduced or acting during execution phase of treatment, i.e., daily patient setup
and intrafractional motion, with day-to-day variations in magnitude and direction [10, 14].
External-beam RT of lung cancer is a form of localised treatment [17] that demand as
a prerequisite high geometrical accuracy for its success. However, owing to the treatment
workflow [9] and fractionated nature associated with the treatment of mobile tumours, respi-
ration and its variations can present a series of limitations at each stage of treatment process
[18]: (i) imaging, (ii) treatment planning and (iii) delivery.
Imaging and Treatment Planning
Accurate imaging is a prerequisite for accurate treatment planning and delivery [21]. How-
ever, respiration-induced motion during initial image acquisition can give rise to a series of
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imaging artifacts, which may in turn translate into treatment planning uncertainties, lead-
ing to a poor definition of microscopic spread of the tumour, degrading target/normal tissue
delineation accuracy [18, 41]. Delineation uncertainties are purely systematic (affect all frac-
tion in same way) [10], and have adverse affects on the selection of safety margin and dose
calculation during treatment planning.
Different imaging artifacts observed during conventional (non-time resolved) computed
tomography, i.e. partial volume effect (image distortion) and image blurring, have been
reported in the literature [10]. Moreover, although it is undeniable that the introduction of
4D computed tomography (4DCT) into clinical routine has improved image quality, providing
time-resolved data sets with reliable spatial-temporal information of patient anatomy, there
are some residual errors which still remain. For example, the patient may breath at a different
level during delivery than of during imaging [34], or the tumour will be targeted at another
arbitrary position that had during imaging [10]. Furthermore, variability in tumour motion,
such as changes in mean tumour position (baseline drift), have added an extra degree of
complexity to time-resolved imaging modalities that account for the effects of respiration.
Baseline drifts are not visible under 4DCT as reported in the work by Sonke et al. [38].
Set-up
Tumour motion influence both systematic and random setup errors [10, 13, 14]. Van Herk
et al. [10] reported that motion of skin relative to internal organs was a major limiting
factor preventing reproducibility of patient setup. With the systematic component mainly
due to the patient setup with regards to skin markers during imaging, whereas the random
component due to day-to-day variations in the reproducibility of the patient setup during
delivery. Recent Image-guided setup protocols, such as those using cone-beam CT (kV and
MV) imaging, have the potential to reduce systematic and random errors [11, 40]. Studies
by Wolthaus et al. [40] and Guckenberger et al. [11] have indicated that by targeting
the soft-tissue tumour itself (using kV CBCT) and bringing its mean position to isocentre
prior to delivery, the systematic component can be largely eliminated, leaving the random
component unattended (intrafractional tumour motion), which can be considered as random
error, requiring smaller margins for its compensation.
Delivery
Dose delivery in the presence of intrafractional motion leads to dose blurring over the direc-
tion of motion, which is the dominant effect on dose distributions [33], resulting in under-
dosage in the tumour and overdose of surrounding healthy tissue and other organs at risk
(OARs). Interfractional motion, such as in the case of systematic changes in mean tumour
position (baseline drifts) [18, 34, 42], on the other hand causes a shift of dose distributions
relative to its planned position [18]. In addition to this, respiration may also lead to spatial
deformation of dose distributions, such as, interplay effects [33] during IMRT. Moreover,
asymmetric deviations in the shape of dose distributions are also possible, which are not
negligible for motions amplitudes 10 mm, requiring nonuniform margins for compensation,
as discussed in the work by van Herk et al [43].
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Overall, the dosimetric implications are such that random errors results in blurring of
dose distributions while systematic uncertainties result in a shift of dose distributions relative
to its planned position [10, 14, 34, 40], as shown in Figure 2.2 (b). More importantly, the
magnitude of the shift may in some cases lead to marginal miss of target in the way that the
tumour moves away from the high dose region, which is a major limiting factor for motion
management techniques designed to facilitate the reduction of treatment margins, such as
gated radiotherapy, which will be discussed in section 2.3.3. Furthermore, it has been noted
in the literature that effects of systematic errors on dose distribution are greater than those
of random errors, which may require 3 to 4 time larger margins than random errors [10].
Figure 2.2: (a) Systematic uncertainties in mean positions (black dots) and random errors
represented by the deviation about mean (error bars). (b) Random errors lead blurring while
systematic errors lead to a shift of the dose distribution (Figures taking from Ekberg et al.
[13] and van Herk et al. [14])
2.3 Management of Respiration-induced Motion
2.3.1 Rationale for Control of Respiration
External-beam RT of lung cancer is a form of localised treatment [17] that demand as a
prerequisite high geometrical accuracy for it success at all stages of treatment workflow:
imaging, treatment planning and dose delivery. However, as described above in section 2.2,
different uncertainties are inherent in the treatment process, which degrades the accuracy and
effectiveness of RT. Typically, all these uncertainties are compensated with large margins
[12, 13, 14]. This, in turn increases the exposure of surrounding healthy lung tissue and
other OAR to high levels of toxicity [11, 15, 16] increasing the normal tissue complication
probability (NTCP).
Furthermore, the increase in data which support the dose-response relationship has pro-
vided the grounds for the consideration of the use of doses higher than those used con-
ventionally for treatment of tumours in the lung with RT. Different escalation dose studies
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have reported improved local control and survival rates when applying doses higher than
conservative doses of (60 -66 Gy) [3]. Dose escalation requires high precision in targeting
of tumours. However, this dosimetric gain can be obscured by limits imposed by normal
tissue complications [4]. Moreover, dose escalation can be potentially even more detrimental
compared to conventional doses in case of geographic miss of the tumour caused by error
induced by respiration during dose delivery.
The challenges presented by respiration have prompted the development of more repre-
sentative imaging modalities, as well as delivery techniques to mitigate the effects caused by
respiration and hence improve local control of tumours in the lung. The following section is
limited to introduce the motion management approaches that were used for this thesis.
2.3.2 Treatment Planning Solutions
Arguably, technological advances have enabled the development of sophisticated treatment
systems and techniques, such as the Mitsubishi real time radiation therapy (RTRT) system
developed by Shirato et al. [44], which have shown superior accuracy and management of
pulmonary tumours, compared to other treatment modalities lacking of direct monitoring of
the tumour during dose delivery. However, such high-precision systems are not yet an off-the-
shelf available technology for most clinical institutions due to increased expenses associated
with their clinical implementation [45]. Subsequently, treatment planning solutions, regarded
as motion-encompassing methods [18, 41], for motion compensation have been developed,
which are of relevance for clinics lacking of dedicated respiration management devices. On
the other hand, some studies have proposed that it may be sufficient to account for intrafrac-
tional tumour motion during treatment by applying motion-encompassing methods [18, 41].
However, these techniques rely on the robustness of imaging, with reliable spatial-temporal
information regarding the patient’s internal anatomy over breathing cycle, such as in the
case of 4DCT, for treatment planning.
The International Commission on Radiation Units (ICRU) Report No 62 [12] guidelines
for determining the volumes have been applied to the treatment of mobile tumours in the
lung, as shown in figure 2.3. The gross tumour volume (GTV) is the gross demonstrable
extent of malignant growth, which consists of the primary tumour and possible other metas-
tases where the tumour cell density is the greatest. The clinical target volume (CTV) is the
tissue that contains the GTV or area believed to harbour the micrometastasis. The PTV is
the geometrical concept, defined to select the appropriate beam arrangements and sizes to
ensure that the CTV receives the prescribed dose, which is defined by adding extra margins
to the CTV to compensate for set-up uncertainties (i.e. patient positioning and alignment
of treatment beams during treatment planning and delivery), as well as internal geometric
variations (i.e., motion induced by physiologic processes). This gives rise to the internal
target volume (ITV), considered as an intermediate to construct the PTV from CTV. This
is an extention of the CTV that has been added to explicitly compensate for the movement
and variations in the shape of the tissue contained in or adjacent to the CTV, such as motion
due to respiration, heart beat, and movement of the bowels [12].
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Figure 2.3: Definition of treatment volumes according to the ICRU Report 62.
Moreover, the definition of the ITV by means of 4DCT has further enabled the generation
of more representatives ITV for treating tumours in the lung. 4DCT data sets can be
analysed to determine the tumour motion range for treatment planning and the relation of
tumour motion to other organs. This in turn has allowed the characterization and design
of patient-specific treatment volumes and dose conformity compared to population-based
isotropic margins.
2.3.3 Treatment Delivery
Respiratory-gated RT
Respiratory gated radiotherapy (RGRT) is a relatively new technique used to reduce and/or
mitigate the effects of respiration-induced motion [3]. In RGRT, the delivery of radiation
is synchronized to a specific portion of the respiratory cycle [3, 18, 41]. The delivery of
gated beams can be synchronised to either a particular position in the respiratory cycle
of the actual tumour/or substitute (amplitude-based gating), or phase of the respiratory
cycle (phase-based gating) [3]. The onset and duration of the gating window relies on
the respiratory signal, which can be acquired either externally by a sensor, i.e., pressure
belt, optical reflector, or by fluoroscopy of internal fiducial markers. The respiratory signal
is assumed to be representative of the tumour motion, from which information regarding
tumour internal trajectory and phase over the respiratory cycle can be inferred. Normally,
a duty cycle, which is the ratio of beam-on to total treatment time, between 30% to 50% is
used [18, 29, 41]. The gate is set to the portion or phase of the breathing cycle where motion
is observed to the least and/or more stable and reproducible position, i.e. end-of-exhalation
phase.
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Depending on the type of surrogate used to acquire the respiratory signal, gating systems
can be classified into external-/internal-based gating [29]. Internal based gating is an inva-
sive treatment approach that uses internal surrogates (fiducial markers) implanted in or near
the tumour site, which are tracked by either on-board or external fluoroscopic kilovoltage
(kV) x-rays systems, to derive the tumour position and guide the delivery of gated treat-
ment beams [18]. One example of such system is the Mitsubishi/Hokkaido real-time tumour
tracking system (RTRT) developed by Shirato et al [44]. On the other hand, gating based on
external surrogates is a non-invasive technique that relies on external respiratory monitors
to indirectly derive an estimate of the internal tumour position [18, 29, 46, 47]. Based on the
acquired respiratory signal the delivery of treatment fields can be either phase/or amplitude
gated. Different research groups have investigated several external surrogates for deriving
tumour position [46], and developed techniques based on the type of surrogate employed.
Two widely commercialized systems [48] are : (i) the real-time position management (RPM)
respiratory gating system (Varian Medical Systems, Palo Alto, CA); (ii) the ANZAI respira-
tory gating system (Anzai Medical, Japan). Both systems rely on the external monitoring of
the abdominal wall motion, mainly limited to the 1D anterior-posterior direction, to provide
a correlation of the tumour position. Figure 2.4, shows some of the major components of
the Anzai gating system which was used for work. The operation of this system will be
described in section 3.1.2.
Figure 2.4: (a) The Anzai gating system with a pressure sensor a(1), belt a(2) fastened
around patient to record the respiratory signal, and sensor port a(3). In (b), the display
window showing the respiratory signal b(1), gating window b(2), gating signal b(3) and beam-
on signal b(4).
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Tumour Tracking
Real-time tumour tracking is one of the most advanced motion compensation methods for
the management of respiration induced tumour motion [9]. In an ideal RT procedure, dose
delivery would be dynamically shifted to accommodate or follow intra-fractional changes in
tumour position. This will eliminate the need for additional margins, otherwise required
to compensate for intrafractional tumour motion, maximizing dose delivery efficiency by
maintaining a 100% beam-on duty cycle [18, 49]. To accomplish this, a tracking system
should be able to [16, 49]: (i) image the tumour/ surrogate [50], (ii) determine or track
tumour position directly [16] or indirectly [51], (iii) predict tumour position to allow for
system’s mechanical and computational delays [37], and (iv) adjust treatment parameters.
All this has to be conducted in real-time.
Existing methods for the determination of target position can be grouped into three
categories [39, 52]: external surrogate based [24, 51]; internal surrogate based (implant
markers) [44, 53]; and markerless [16]. The information regarding tumour position is then
coupled through a control loop to repositioning system that will adjust or shift the position
of the beam relative to the moving target [49]. This can be accomplished, either by adjusting
the MLCs, such as in the case of Dynamic MLC delivery; or by shifting the treatment table
with a robotic couch [42]. An example of such dedicated systems, which is relevant to this
thesis (chapter 4 and 5), is the Wuerzburg Adaptive Tumour Tracking System (Figure 2.5).
Figure 2.5: Schematic representation of the Wuerzburg Adaptive Tumour Tracking System.
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The objective of this system is to compensate tumour motion in real-time by repositioning
the patient, using a HexaPOD robotic couch with six degrees of freedom, relative to the
stationary treatment beam. Repositioning of the couch is guided by 2 independent means.
Megavoltage imaging, in which the tumour is automatically tracked in images acquired with
the electronic portal imaging device (EPID) without the aid of markers using a dedicated
tracking software, denoted PortalTrack, whose suitability for the verification of RGRT will be
investigated in chapter 4 and 5. At the same time the external signal is obtained by tracking
optical markers placed on the patient abdomen by an infrared camera (external signal). Both
the internal and external signals are sent to a control system, which is used to predict the
future tumour position. Using the prediction, appropriate repositioning commands are sent
to the HexaPOD [42].
2.4 Issues with Motion Management Techniques
It is difficult and technically challenging to determine the tumour position directly, one has
to rely on monitoring surrogates (external/internal) for tumour motion, i.e., abdominal wall,
diaphragm, which are assumed to closely correlate with the actual tumour motion [18]. If
a surrogate of tumour motion is used for the purpose of beam gating or tumour tracking
without being able to directly monitor the tumour, and because of the above-mentioned
variations in tumour motion that may take place intra-/inter-fractionally, this may result in
uncertainties in the mechanical coupling between surrogate and tumour.
With regards to RGRT, although internal-based gating modalities allow the direct and
more accurate internal localization of the tumour in 3D with improved image contrast and
high sampling rate, compared to megavoltage imaging, day-to-day migration of markers is
also possible [32]. As a result of this, more than one marker is required to measure their
displacement relative to each other and hence rule out the possibility of marker migrations.
This in turn increases the risks of infections, i.e. pneumothorax [49]. Another concern is the
additional patient exposure to radiation dose during fluoroscopic tracking of markers, which
is to have a greater impact on longer treatment session, such as in the case of hypofractionated
RT, resulting in clinically unacceptable accumulative levels of imaging dose to patient [29, 49].
Because of the invasiveness, complexity and expenses associated with this procedure, many
clinicians are reluctant to adopt this technique in clinical routine [15].
In the case of motion management modalities that rely on the monitoring of external
surrogates, i.e., external-based gating, for deriving tumour position, the degree of inter-
nal(tumour)/external(surrogate) correlation represents the major source of geometric uncer-
tainty. It is not clear how accurately the external surrogate represents the extent of internal
tumour motion [3]. For example, the linear 1D motion of the abdominal wall may not
accurately reflect the internal 3D tumour motion.
Effects of Correlation Variations
In the case of external-based gating, it has been identified that in clinical cases most patients
exhibit unsynchronised amplitude variations, baseline drifts and time shifts between internal
tumour motion and external surrogate signal [45, 46, 47, 54]. Figure 2.6 gives examples of
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discrepancies in the correlation between the internal tumour and external surrogate, which
may arise during external-based gating, reported in the work of Wu et al. [47].
Figure 2.6: Examples of discrepancies in the correlation between the internal/external signals
with phase shifts (a), baseline drifts (b) and amplitude variations (c). (Figure taken from
Wu et al. [47])
Furthermore, it has been documented that the presence of intra/interfractional variations
in tumour mobility and patient’s breathing pattern and reproducibility further degrades the
degree of internal/external correlation, decreasing the accuracy and effectiveness of RGRT.
Such types of variations add uncertainty and delay to treatment, which can lead to false
positives and false negative [29, 47]. During a false positive event the radiation beam is on
while the tumour is out of the gating window (marginal miss) while during a false negative the
beam is off while the tumour is inside the gating window. The clinical implications are such
that during false positive more dose is given to healthy tissue and other critical structures
whereas false negatives prolongs treatment, which in turn may lead to underdosage of the
tumour. Variations in the external breathing levels and patterns a patient may be identified
by only monitoring the breathing signal during treatment, and once a irregularity is identified
the treatment can be interrupted. However, accounting for variations in the internal tumour
trajectories during treatment, a clinical tool is required in which breathing-induced tumour
motion can be imaged and quantified to the extent that variations such as baseline drifts
and shifts can be identified [45].
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2.5 Summary
This chapter introduced some of the major issues presented by respiration and related un-
certainties, which limit the success of radiation therapy of tumours in the lung. Motion
management techniques play an important role in the compensation of respiration-induced
motion. One of these newly emerging techniques, which is being commercially implemented
worldwide, is RGRT. RGRT holds promise to reduce the incidence of healthy tissue toxicity
and improve the TCP. However, there is some controversy with existing gating techniques
that has been reported in the literature and, which needs to be addressed. In the next
chapter, the suitability of RGRT to mitigate the effects of respiration-induced motion will
be investigated.
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Chapter 3
Respiratory-Gated Study
This investigation is part of the University Medical Center Hamburg-Eppendorf (UKE)’s
preliminary research on RGRT for its potential implementation into clinical routine. RGRT
is a relatively new treatment technique for the management of mobile tumours in the tho-
rax and abdomen [18, 24]. It has the potential to mitigate the effects of respiration induced
motion, reducing the incidence of healthy tissue toxicity by facilitating the reduction of treat-
ment fields, which may ultimately allow for dose escalation [23, 25]. Although external based
gating systems are commercially available, there are some issues as to how well monitoring
an external surface correlates to the internal tumour motion, which has discouraged many
users [46, 47, 54]. Therefore, it is essential to conduct an assessment of the performance of
such systems in order to identify their capabilities and limitations before they are introduced
into the clinical routine. This may then lead to the design of treatment protocols, such as to
establish criteria to select patients, i.e. patients with regular breathing, who are to benefit
the most from this technique and those that might not, i.e. patients with irregular breathing.
For this study an external-based gating system (Anzai AZ-733V, Anzai Medical Solutions,
Japan) was available and its suitability to reduce the effects of intrafractional breathing
motion on dose distributions investigated. In addition to this, its performance under the
influences of discrepancies in the correlation between the internal target motion and the
external signal, which has been acknowledged as a major source of uncertainty for such
treatment modalities and become the source of much debate [30, 45, 46], was also explored.
This was accomplished by means of phantom studies and film dosimetry.
3.1 Method and Materials
3.1.1 Motion Phantom
An in-house developed motor-driven motion phantom, consisting of a movable wagon carry-
ing a stack (9 cm x 7 cm x 7 cm) of water equivalent RW3 (PTV, Freiburg, Germany) plates
each 1 cm thick, was used for the simulation of a series of periodic trajectories (see Figure
3.2(c)). This phantom has the ability to simulate coupled motions in two dimensions (2D)
along the anterior-posterior (AP) and superior-inferior (SI) directions, with adjustable user-
defined amplitude (A) and period (T) of oscillations. The motion patterns are generated by
the rotation of eccentric discs, designed based on observed 4DCT data of patients with lung
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tumours [55]. In addition to this, a contrast material (with a diameter 2 cm and thickness
of 2 cm), serving as tumour substitute, was built-into the stack of plates (see Figure 3.1
and 3.2). The centroid of tumour surrogate was designed to be located at position x = 3.5
cm; y = 4.5 cm; and z = 4 cm relative to the stack of plates (between plates 4 and 5).
The ICRU reference point was set to this point. Overall, all the motion patterns generated
by the dynamic phantom are transmitted to the tumour substitute, which is moved in 2D
in both the SI and AP directions and in synchrony with the motion phantom. It is worth
indicating that this tumour substitute was originally designed for the purpose of running
tumour tracking simulations, which will be discussed in the next chapter, due to its high
contrast. Only for consistency in the overall aim of this work the same contrast material
(tumour substitute) was used for this gated study.
Figure 3.1: Stack of water equivalent RW3 plates with tumour substitute embedded within it.
Film was placed on a reference plane, with the ICRU reference point set to centroid of the
tumour substitute, which was in the plane of the film.
Target Paths
Different sinusoidal motion paths of tumour substitute were defined by a given peak-to-peak
motion amplitude (A) and period (T) of oscillation. This study was only concerned with
motion in the SI direction since it has been indicated to be the predominant direction of
motion observed in clinical cases [13, 18, 27, 32], as well as, with relatively large motion am-
plitudes (A ≥ 10 mm) of the tumour substitute (target). The justification for the simulation
of large motion amplitudes for this experiments are based on the literature [11, 34], which
has suggested that gated RT is of more relevance for the treatment of tumours exhibiting
large motion amplitudes. In a study by Engelsman et al. [34] the investigators noted that
the relationship between the margins required for the compensation of intrafractional motion
was not linearly proportional to the peak-to-peak motion amplitude (A), but quadratic. It
was observed that small margins (≤ 2 mm) were sufficient for the compensation of breath-
ing amplitudes ≤ 10 mm. However, for motion amplitudes ≥ 10 mm these margins would
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increased rapidly (quadratically). In a more recent study, Guckenberger et al. [11] also re-
ported a quadratic relationship between tumour motion amplitude and the margins required
for the compensation of cumulative dose loss to treatment planning volumes as result of
respiratory induced tumour motion.
Figure 3.2: (a) The orientation of room coordinates with the motion phantom set at delivery
position with pressure sensor belt fasted around the main platform to acquire the 1D respira-
tory signal used to gate the linac, (b) the Anzai display window monitoring the respiratory
signal which was used to direct the onset of gating signal sent to the linac, and (c) the major
components of motion phantom with the tumour substitute to be irradiated
3.1.2 Gated Delivery
The Anzai gating system, which is commercially available, was used to monitor respiratory
motion and gate the delivery of treatment fields on a linear accelerator. This system uses
a pressure sensor belt to monitor the external respiratory patterns (pressures changes) in
real-time. The pressure sensor belt was placed around the main platform where the movable
wagon rests (see Figure 3.2(a)). This platform was only exposed to changes in position along
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the AP direction, which at the same time was responsible for the AP motion component
of the tumour substitute. This way, the pressure sensor was only limited to detect changes
in motion along the AP direction resulting in a 1D signal (breathing signal). In a real
clinical procedure, the belt is normally placed around the patient’s abdomen and let to
monitor changes in the abdominal wall of the patient, resulting in an 1D signal, which
is used to trigger the accelerator during gated treatment or for slice sorting during image
reconstruction in 4DCT.
This signal is transfered to the sensor port and then to a processing deck where it is
digitized and then input into the control computer for display and definition of gating pa-
rameters. In the display console, the respiratory signal is displayed between a 0% to 100%
range, spanning from the end-of-exhale (EOE) to end-of-inhale (EOI) phases of respiration.
To gate the linac, a gating window was defined on the external signal by setting a predefined
amplitude threshold level on the respiratory signal, defining a range of the respiratory signal.
Any time the signal falls below the threshold of the gating window the linac is ON (beam-on
time); otherwise OFF. Gating windows of different sizes can be defined by setting different
amplitude levels (between the 0% to 100% range) on external signal, as shown in Figure
3.3. Applying a 100% gating level means that the gate remains on over the whole breathing
cycle, whereas for instance a 75% gating level means that the gate remains open for the 75%
range of breathing signal.
Figure 3.3: Anzai display console showing the respiratory signal (a), the gating signal (b),
and the beam-on signal sent to linac. The respiratory signal is normalized to 100%, with
zero representing the EOE and 100 the EOI phases of respiration. For this example, a 25%
amplitude threshold level was set to the signal with the gating window encompassing the EOE
phase of respiration.
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For the phantom, the breathing signal (0% to 100% range), was equated to the total
motion range (peak-to-peak displacement along SI direction) of target, which represented
the longitudinal distance encompassed between the EOE and EOI positions of the target
during dose delivery. Therefore there was a one-to-one (1:1) correlation between the changes
in position of target and the breathing signal.
3.1.3 Treatment Planning
A 4DCT scan was acquired of the motion phantom with a helical 24-slice scanner (Somatom
Sensation Open, Siemens Medical Solutions, Erlangen, Germany) together with a pressure
belt sensor for generation of breathing signal. After the amplitude-based reconstruction of
projections, eight phases were reconstructed. The recorded breathing signal was extracted
from the system’s data bank for analysis. The probability density function (PDF) of the
signal, whose shape carries characteristic information of the motion signal indicating where
the target spends more time, was used as criteria to select the corresponding phase from the
4DCT dataset for purpose of treatment planning.
The CT study corresponding to the EOE phase was chosen for treatment planning. A
6MV single-beam conformal plan was generated using the planning system XIO CMS, with
the gantry set to 0 ◦ with beam direction perpendicular to the movement direction of the
target in SI axis. The ICRU reference point was set to the centre of mass of the tumour
substitute at a depth of 3 cm relative to stack of plates (see Figure 3.1). The MLCs were
conformed to the geometry of delineated PTV with a field edge-to-PTV distance of 0.8
mm. The idea was to conform the 95% isodose level around PTV in the coronal central
plane through the target centroid, delivering a prescribed dose of 2Gy to the ICRU reference
point. Figure 3.4 shows the 4DCT data with the target contoured at both ends of the
motion range between EOE(green) and EOI (red) phases of respiration. Note that both
the target and the movable wagon move relative to the beam direction. The resulting dose
dristributions obtained from treatment planning process are shown in Figure 3.5.
Figure 3.4: 4DCT of 2D phantom with tumour surrogate contoured at EOE phase (green),
EOI phase (red), and middle phase (blue), and the internal target volume (ITV) encompass-
ing the peak-to-peak excursion of the target (yellow).
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Figure 3.5: The planned dose distributions in the plane of the film with the tumour substitute
set at the EOE phase.
3.1.4 Data Analysis
Film Dosimetry
Film measurements were performed in the coronal central plane, which contained (approx-
imately) the tumour substitute’s centroid, using GafChromic EBT2 films, as indicated in
Figure 3.1. To convert the irradiated films to dose distributions a dose response curve was
first obtained from one film for a pattern of nine 2 cm x 2 cm fields arranged in a 3 x 3 patter
with a 1 cm gap between each field. Each field was irradiated with a different number of
monitor units (MUs), corresponding to a dose range between 0.16 to 3.16 Gy (see Table 3.1).
After irradiation the film was stored for 24 hours, during which the self-developing process
took place. After this period, the film was digitized using a commercially available flatbed
scanner Model ScanMarker 8700 (Microtek, Hsinchu, Taiwan). The scan was stored as 48
bit RGB images in the tagged image file format (TIFF). From this TIFF data file, the red
channel was extracted and corresponding scan values, resulting from the 0.16 to 3.16 dose
range, were obtained using in-house MATLAB (Mathworks, Inc., Natick, MA, USA) rou-
tines. A first order polynomial of first degree order was fit to the points, resulting in a dose
response curve, as shown in Figure 3.6. The fitting of a first order polynomial and resulting
dose response curve is a standard procedure, which is conducted at the Department.
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Table 3.1: Irradiated dose values to obtain the dose response curve
Field Dose (Gy)
1 0.16 ± 0.01
2 0.53 ± 0.01
3 0.91 ± 0.01
4 1.29 ± 0.01
5 1.67 ± 0.02
6 2.04 ± 0.03
7 2.44 ± 0.04
8 2.79 ± 0.04
9 3.16 ± 0.05
Figure 3.6: Schematic representation of irradiated film with a pattern of nine 2 cm x 2 cm
fields arranged in a 3 x 3 pattern, and resulting dose response curve
All film measurements performed using the motion phantom were irradiated one at a time,
digitized in the same way as described above, and converted by means of the dose response
curve into a dose matrices (dose distribution), and retrospectively analysed. Figure 3.7 gives
two examples of dose distribution extracted from irradiated films using the information from
dose response curve and Matlab-based routines.
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Figure 3.7: Two examples of resulting dose distributions obtained from irradiated films in
the absence (a), and in the presence (b) of intrafraction breathing motion simulated by the
motion phantom.
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Dose Comparison Criteria
To evaluate the effects of intrafractional breathing motion the resulting dose distributions,
obtained under the effects of different motion components simulated by the motion phantom,
were compared against a reference dose distribution. This reference dose distribution was
obtained from a delivery session having the tumour substitute stationary and set at its
planned position, which modelled an idealised treatment procedure without the influences
of breathing induced-motion on dose to the PTV. Note that initial comparisons between
the planned and the measured reference dose showed a dose deviation of approximately +
2.5% between the two. Although this dose comparison was repeated 6 times (for 6 different
irradiated films with target stationary at reference position), this dose deviation remained
constant for all the 6 films. This was attributed to systematic uncertainties which may have
been introduced throughout the experiment, i.e., scanner inistability and scanning artifacts,
the small geometry of target and its set up, etc.
Differential Dose Area Histograms
To better appreciate the differences between dose distributions resulting from gated and un-
gated dose delivery differential dose area histograms (DAH) were designed. The construction
of dose area histograms were based on the approach presented in the work of Engelsman
et al. [35]. Differential dose area histograms were constructed for both the PTV and area
outside of it. To accomplish this, the area enclosed by the 95% isodose level (IDL95%) in the
reference static dose distribution was chosen to represent the PTV, receiving a dose ≥ 95% of
the prescribed normalised dose, and with 100% target coverage. This area served as reference
region, which was superimposed over the dose distribution to be evaluated. Then the dose
values within the reference region were compared with those enclosed by its projected area
over the dose distribution being evaluated. Figure 3.8 shows a schematic representation of
the procedure used to construct dose area histograms for the evaluation of resulting dose
distributions, relative to the reference dose distribution.
All the dose values within the reference PTV region were extracted and put into dose
bins of 1% dose intervals generating a DAH, representative of the static reference dose
distribution, with an area equivalent to the total number of dose values enclosed within
selected reference region, which was normalised to 100%. Then, both the reference (static
case) and the dose distribution to be evaluated were superimposed, and all dose values
enclosed by the projected PTV area over the dose matrix being evaluated were extracted
(see Figure 3.8). These extracted dose values were equally put into dose bins to generate
a DAH representative of the dose distribution being evaluated. DAHs were contructed for
all dose distributions and used to evaluate the influence of intrafractional motion and its
variation (baseline drifts) during un-gated and gated beam delivery.
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Figure 3.8: An example of the procedure for the evaluation of dose distributions using DAHs.
First both the reference (a) and the dose distribution to be evaluated (b) were aligned around
the EOE, then the area enclosed by the IDL95% in the reference distribution (c) was se-
lected as reference PTV area. This is superimposed over the distribution being evaluated in
(d). Only the dose values within the reference region of its projected area are used for the
construction of DAHs.
3.2 Intrafractional Motion and Gated Delivery
The dominant effect resulting from intrafractional motion is the blurring of dose distribu-
tions [33, 34]. Blurring leads to an enlarged beam penumbra and hence to less conformal
dose distributions, which may have more detrimental effects on highly conformal treatments
techniques such as intensity-modulated radiotherapy where steep dose gradient are tailored
around OARs. The magnitude of blurring depends on the characteristics of motion, as well
as the steepness of dose gradient and density of the medium [33, 34, 35]. The objective of
this section was to investigate the effects of intrafraction motion on dose distributions and
the suitability of gated beam delivery to minimise motion-induced blurring effects.
27
3.2.1 Gating Level Variations
This part of the study investigated the effects of applying different gating levels during dose
delivery. For comparison both un-gated and gated dose delivery sessions were performed.
The tumour substitute’s centroid was positioned at the isocentre and set to oscillate with
a peak-to-peak motion amplitude of ≈ 18 mm in the SI direction, perpendicular to beam
direction with gantry at 0◦, a breathing rate of 15 breaths per minute (f = 15 breath/min),
corresponding to a 4-second long breathing cycle, which is within the range of clinically
observed values (2.7 to 6.6 sec) [27].
Six delivery sessions (1-6) were conducted. For session 1, dose delivery was performed in
the absence of intrafraction motion (target stationary centred at EOE phase), resulting in a
static dose distribution. This static dose distribution served as reference against which the
other dose distributions were compared to. For the remaining sessions the tumour substitute
was allowed to move during dose delivery. Session 2 (dynamic delivery) corresponded to
dose delivery without applying any control for motion (un-gated), which can be interpreted
as allowing the delivery of dose over the whole breathing cycle (100% duty cycle). For the
remaining sessions (3-6) an amplitude-based gating approach was performed applying gating
duty cycles of 12%, 38%, 50% and 75%. Figure 3.9 shows the relative dose distributions
resulting from delivery sessions (1-6). By comparing both the static (reference) and un-
controlled (un-gated) dynamic distribution, it can be observed that intrafractional motion
results in a degradation of dose conformity manifested by an enlarged penumbra at the edges
of the field in the direction of motion. Conversely, with gating, the blurred dose distribution
(dynamic distribution) resulting from un-gated delivery of dose is reduced progressively as
smaller gating levels are applied. For instance, applying a 12% gating duty cycle resulted in
a dose distribution that closely resembled that of the static distribution.
The dose profiles through the PTV along the SI direction, containing the target centroid
(white dashed line drawn on static dose distribution in Figure 3.9), are shown in Figure 3.10.
The PTV represents the area enclosed by the prescribed IDL95%, with the target centred
at the EOE phase of respiration and static. The target moves along the SI direction from
EOE to EOI phases of respiration a certain distace (∆SI ) and perpendicular to the beam
direction. Since the gating window was defined to encompass the EOE phase of respiration,
any time the target moved towards the EOI the area of the film to the left of the PTV was
exposed to more dose, whereas the area to the right of the PTV to less dose. This explains
the shapes of dose profiles, which have been smeared towards the EOE phase (to the left of
the PTV). The profile correponding to the un-gated dynamic dose delivery shows that the
gate (beam-on time) remained on over the whole breathing cycle length, which resulted in
maximum dose smearing towards the left of the PTV. Less dose blurring can be observed for
gated deliveries in which the gate was opened for only 75%, 50%, 38% and 12% of breathing
cycle length.
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Figure 3.9: Comparison of dose distributions (in pixels) corresponding to delivery sessions (1-
6). Reducing the gating level decreases dose blurring effects (dynamic distribution) resulting
in improved dose conformity. The white dashed line indicates the position at which the
penumbra widening was measured for each dose distribution.
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Figure 3.10: Dose profiles along the superior-inferior (SI) through target centroid for delivery
sessions (1-6). The change in position of tumour substitute during dose delivery (∆SI)
represents the peak-to-peak motion amplitude. The penumbra widening (∆p) was measured
between the 80% and 20% isodose level.
Table 3.2 shows a summary of measured parameters for penumbra widening (∆p) and
their relative change with respect to the reference distribution (static case), as well as delivery
time and resulting treatment efficiency. Intrafractional motion without any control (dynamic
case) leads to an increase in penumbra by up to 121%, relative to static delivery. On the
other hand, for applied gating levels of 75%, 50%, 38% and 12%, the blurred penumbra
was reduced to 158%, 144%, 131% and 120%. This was at the expense of an increase in
treatment efficiency which was reduced to 73%, 71%, 69% and 51%, respectively. Such
prolonged treatment times represents a major disadvantage of gated delivery, compared to
other motion management techniques such as tumour tracking. It has been suggested that
such prolonged treatment times are not only relevant in terms of patient treatment output,
but that it may also add uncertanties to the treatment, i.e. patient setup, as result of patient
discomfort.
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Table 3.2: Measurements of penumbra widening (∆p) and treatment efficiency for delivery
sessions(1-6)
Session Delivery Duty Penumbra (∆p) Delivery
# mode cycle mean perct.∆ time efficiency
(%) (mm) (%) (sec) (%)
1 un-gated ( static) - 5.1 100 64.5 100
2 un-gated (dynamic) - 11.2 221 - -
3 75 8.0 158 81.7 73
4 gated 50 7.4 144 83.1 71
5 38 6.7 131 84.4 69
6 12 6.1 120 95.9 51
Overall, the presence of intrafractional breathing motion results in an underdose of the
PTV and overdose of the area outside of it, representing surrounding healthy tissue. Figure
3.11 compares the effects of intrafractional motion on the dose to the PTV (central plane
of the PTV ) corresponding to delivery sessions without control (dynamic cases) and with
control for respiration with duty cycles of 75%, 50%, 38% and 12%, relative to the static
ideal case (no-intrafractional motion). From these plots, it can be observed that dose delivery
without any control result in the PTV receiving less than 95% of the prescribed dose (decrease
in TCP), with a decrease in the minimum prescribed dose from 94% (static case) to 49%
(dynamic case). Conversely, gating improved PTV coverage, increasing the minimum dose
to the PTV from 49 (un-controlled dynamic case) to 73, 79, 81, and 86% for gating level of
75%, 50%, 38% and 12%, respectively.
Furthermore, with presence of intrafractional motion the percentage of the PTV area
receiving a dose less than 95% of the prescribed (area enclosed by the IDL95%) decreases
from 3.6% (static case) to 41.8% (dynamic case), whereas with gating the underdosed area
inside the PTV is decreased from 41.8 (dynamic case) to 28.2%, 20.3%, 15.8% and 10.8 % for
gating levels of 75%, 50%, 38% and 12%, respectively (see Table 3.3). These improvements in
the coverage of the PTV observed with gated beam delivery are correlated with improvements
in dose conformity, and hence a decrease in overdose area outside PTV, which represents
surrounding healthy tissue.
31
Figure 3.11: Comparison of dose area histograms (DAHs) of the central plane (plane of the
film) of the PTV (area enclosed by the IDL95%) for dose delivery sessions, without (un-gated)
and with control for respiration using gating. The PTV dose area histogram corresponding to
static dose distribution served as reference, which is compared to dose DAHs resulting from
un-gated (a) and gated dose delivery with duty cycles of 75% (b), 50% (c), 38% (d), and
12% (e), respectively.
Alternatively, if target coverage is to be kept constant when using gating to compensate
for the blurring effects induced by intrafractional motion, the margins designed during treat-
ment planning should be modified. Applying the approach suggested by Engelsman et al.
[34], in which the investigators used the displacement of the prescribed isodose as a measure
to quantify the margins required to compensate for intrafractional motion, measurements of
the displacement of the 95% isodose level (IDL95%) indicate that the treatment portals can
be reduced with gating. Table 3.3 gives a summary of the measurements of the displacement
of IDL95% corresponding to the left-hand and right-hand side of dose profiles from figure
3.10, relative to the static case. This one dimensional analysis indicates that having the
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target positioned at EOE, the field sizes would have to be enlarged by 6.3 mm, 4.6 mm,
4.2 mm, 2.4 mm towards the EOI direction, whereas towards the EOE direction decrease
by 1.8 mm, 1.1 mm, 1.3 mm, 0.7 mm for duty cycles (gating levels) of 75%, 50%, 38% and
12%, respectively. For example, an increase in field sizes of ≈ 3 mm (∆ |right− lefthand|)
would be sufficient to ensure that the target remains within the high dose region during
gated beam delivery with a 38% gating duty cycle at the expense of 31% (from Table 3.2)
decrease in treatment efficiency. This reduction in field sizes with gating may in turn result
in an increase in the sparing of surrounding healthy tissue and other OARs.
Table 3.3: Minimum relative dose to PTV and its percentage area receiving less than 95%
of prescribed dose. Measurements of the displacement of the IDL95% represent the decrease
(-ve) and increase (+ve) in field sizes towards the left-/ and right-hand side direction.
Session Delivery Duty PTV IDL95% displacement
# mode cycle Min. dose Area prcnt. with to Left to Right
(%) (%) dose < 95% (mm) (mm)
(un-gated)
1 static - 94 3.6 - -
2 dynamic - 49 41.8 - -
3 75 73 28.2 - 1.8 + 6.3
4 (gated) 50 79 20.3 - 1.1 + 4.6
5 38 81 15.3 - 1.3 + 4.2
6 12 86 10.8 - 0.7 + 2.4
3.3 Discrepancies in the Internal/External Correlation
The aim of this section was to investigate the effects of the discrepancies in the correlation
between target motion and the ANZAI respiratory signal on gated beam delivery. Variations,
which may arise during delivery, i.e. baseline drifts, can lead to uncertainties resulting in
poor tumour control [40].
Baseline-drifts of 4 different magnitudes (3, 6, 9 and 12 mm) were simulated by making
respective discrete changes to the couch position over fractionated delivery. For a dose of
2Gy, resulting in 212 monitor units (MU), the delivery was interrupted three times, splitting
a single fraction into 4 equally divided subfractions of 53 MUs each. Each time the dose
delivery was interrupted, the treatment couch was displaced a certain distance away from
central beam axis until the whole number of MUs was delivered. The total displacement of
the couch by the end of fraction delivery represents the magnitude of simulated drift (d), as
shown in Figure 3.12. Overall, this resulted in the target centroid deviating caudally away
from its central beam axis and its planned position, while the breathing signal used for the
onset of gated beams remaining regular. A schematic representation of the procedure can
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be observed in Figure 3.12. All measurements performed on the motion phantom had the
target set to oscillate at a frequency of 15 cycles/min and a peak-to-peak motion amplitude
≈ 18 mm.
Figure 3.12: Simulation of baseline drifts along the SI motion direction of tumour substitute.
3.3.1 Effects of Baseline Drifts
To assess the dosimetric impact of baseline drifts on gated beam delivery, all measurements
were performed with a common reference gating duty cycle of 38%. The first delivery session
was performed in the absence of baseline drift, which served as reference. For the remain-
ing sessions a different magnitude of baseline drift was simulated. Figure 3.13 shows the
dose profiles measured in the plane of film resulting from delivery sessions performed in
the absence (blue profile), as well as under the effects of 3 (grey profile), 6 (green profile),
9 (yellow profile) and 12 mm (red profile) baseline drifts. From this figure, it can be ob-
served that baseline drifts diminished the dosimetric gains of gated beam delivery, resulting
from a 38% gating duty cycle. In addition to leading to less conformal dose distributions,
such drifts resulted in a general shift of dose distributions relative to the intended position
(PTVgated 38%dc), which was the region enclosed by IDL95% under a 38% duty cycle, in the
direction and with a magnitude proportional to that of the simulated drift (see Figure 3.13).
With respect to the reference dose profile, baseline drifts led to an increase in penumbra by
10%, 23%, 49% and 70% for simulated drifts of 3, 6, 9 and 12 mm, respectively. Furthermore,
measurements of the displacement of high dose region, showed asymmetric changes in the
position of the IDL95% for the left-hand side (between 1.3 to 7.7 mm) and right-hand side
(between 1.6 to 3.7 mm) dose profiles, as also pointed out in studies by van Herk et al.
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and Engelsman et al. [10, 34]. Moreover, it is interesting to note that the combined (left-
/right-hand side) displacement of IDL95% resulted in corresponding shifts of 2.9 mm, 5.9
mm, 8.9 mm and 11.4 mm, which were within 0.3 - 4.8% in magnitude with those simulated.
From a clinical point of view, such measurements of the IDL95% displacement can be used
to determine the margins required to compensate for the effects of such drifts.
Figure 3.13: Resulting dose profiles measured in the plane of the film, with respect to
PTV(Gated 38%dc), marked by region enclosed by 95% IDL
On the other hand, to assess the the influence of such drifts on relative dose delivered
to region of interest (PTV(Gated 38%dc)), the dose area histograms (DAHs) of the central
plane, corresponding to each delivery session, are also shown (Figure 3.14). Baseline drifts
resulted in the PTV(Gated 38%dc) receiving a dose less than 95% of prescribed dose, while
at the same time increasing the percentage of the PTV(Gated 38%dc) area receiving a dose
of less than 95%. For instance, a 3 mm baseline drift resulted in a decrease in minimum
dose to PTV(Gated 38%dc) from 94% (gated reference in absence of drift) to 89%, as well as
in an increase in area receiving a dose less than the minimum prescribed of 95% from 2.8 %
to 11.1%, respectively. Conversely, for the case of simulated drifts of 6, 9 and 12 mm the
minimum relative dose delivered to PTV(gated 38%dc), with respect to reference DAH (gated
without baseline drift) decreased to 80%, 71% and 66%. Additionally, the PTV(Gated 38%dc)
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area receiving a dose less than 95% increased to 16.2%, 30.1% and 32.1%, respectively. Table
3.4 gives a summary of calculated parameters.
Figure 3.14: Dose area histograms of the central plane of the region of interest (PTV) showing
the effects of baseline drifts on the dose to PTV(Gated 38%dc) during gated delivery with 38%
duty cycle.
Table 3.4: Effects of baseline drifts of different magnitudes on the dose delivered to the PTV
during gated delivery using a 38% gating duty cycle
Delivery Magnitude of Penumbra PTV
mode baseline drift mean perct.∆ min. rel. perct.(%) Area with
(mm) (mm) (%) Dose (%) < 95% rel. Dose
gated - 6.2 117 94 2.8
( reference)
gated 3 6.6 127 89 11.1
38% dc 6 7.4 140 80 16.2
9 8.8 166 71 30.1
12 9.8 187 66 32.1
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3.3.2 Variations in Gating Levels
Different gating duty cycles (12%, 38%, 75%) were tested under the effects of a 6 mm
baseline drift, which was equally applied over each delivery session, in order to investigate
whether such effects could be compensated by only adjusting the gating window. It has been
suggested in some studies [17, 29], by making respective adjustment to gating window so to
accommodate for increases/decreases in residual motion by widening/narrowing the gating
window.
Table 3.5 gives a summary of the calculated parameters corresponding to both un-gated
(static and dynamic) and gated delivery sessions with applied gating duty cycles of 12%, 38%
and 75% under the effects of a 6 mm baseline drift. The dynamic distribution represented the
worst case scenario, resulting purely from the effects of intrafractional motion and baseline
drifts, without applying any control for motion compensation (ungated). With respect to
the reference distribution, a 6 mm baseline drift degraded dose conformity and compromised
PTV(ref) coverage, increasing the penumbra region by 113% and reducing the minimum
dose delivered to PTV(ref) to 66% (see Figure 3.15), while at the same time increasing the
PTV(ref) area with dose less than prescribed to 34.9%. Conversely, with gating the blurring
effects were minimised, reducing the blurred penumbra (un-gated dynamic) by 27.9%, 34.2%
and 40% when applying gating duty cycles of 75%, 38% and 12%, respectively. A similar
trend towards improving dose coverage was observed by decreasing the gating duty cycle.
Overall, the underdosed area was reduced between 46.7 to 72.2% with respect ungated
dynamic delivery (down from 34.9% to 18.6% and from 34.9% to 9.7%) for duty cycles of
75% and 12%. For instance, for a reference 38% duty cycle, the underdosed area was reduced
by almost 62% (down from 34.9% to 13.3%) and minimum dose to PTV(ref) increased to
87% (see Table 3.5).
Table 3.5: Effects of varying gating levels on the dose delivered to the PTV(ref) under the
effects of 6 mm baseline drift
Baseline Delivery Window Penumbra PTV(ref)
drift mode level mean perct.∆ min. rel. perct. Area with
(mm) (%) (mm) (%) Dose (%) < 95% rel. Dose
(un-gated)
- static - 5.3 100 94 3.4
6 mm dynamic - 11.2 213 66 34.9
6 mm 75 8.1 153 86 18.6
6 mm (gated) 38 7.4 140 87 13.3
6 mm 12 6.7 128 88 9.7
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Figure 3.15: Comparison of dose area histograms for delivery sessions with duty cycles of
75%, 38% and 12% in the presence of a 6 mm baseline drift.
Figure 3.16 shows the dose profiles corresponding to sessions delivered under the combined
effects of intrafractional motion and baseline drifts. By inspecting the dose profiles, it can
be observed that applying a 12% duty cycle reduced the effects of baseline drift significantly,
improving dose conformity and PTV coverage. Although, this may be accomplished at the
expenses of a prolonged treatment time associated with the small gating duty cycle applied,
as previously demonstrated in section 3.2.1. Furthermore, when considering the amount of
dose delivered outside the PTV(ref) region, which may be correlated with the amount of dose
deposited in the surrounding healthy tissue or organs at risk, the dosimetric benefits were also
significant. From Figure 3.16, it can be observed that the amount of dose smeared outside
PTV(ref), towards the end-exhalation direction (left-hand side relative to static profile),
could be almost compensated by reducing the gating window from 75% to 38 and 12% dc.
However, because of the effects of baseline drift, reducing the duty cycle resulted in slightly
more dose being delivered to the region outside PTV(ref) towards the inhalation direction
(right-hand side relative to static profile). Moreover, it appears that with smaller duty cycles
(38% and 12%) slightly more dose was concentrated outside PTV(ref) region, compared to
dose delivery with a 75% duty cycle (see Figure 3.16).
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Figure 3.16: Dose profiles measured in the plane of film. The unblurred/static profile (blue
profile) served as reference. The remaining profiles correspond to dose delivery under the
effect of a 6 mm baseline drift without (red profile) and with gating applying duty cycle of 75
(yellow profile), 38 (green profile) and 12% (grey profile).
It is expected that relatively larger magnitudes (i.e. > 6mm) of baseline drifts could
result in a more significant amount of dose being delivered outside PTV(ref) to the extent
that compensating for such discrepancies by reducing the gating window, would not be
sufficient. This observation can be better understood by looking at the dose profiles shown
in Figure 3.17. These profiles were obtained from delivery sessions under the influences of
6mm, 9mm and 12mm baseline drift with control for respiration (gated with a 38% duty
cycle) and without any control for respiration (un-gated). With respect to the reference
distribution, the smearing of the dose distributions towards the EOE (left-hand) direction
were compensated with gating for all the simulated drifts at the expenses of decreased dose
to PTV. However, when considering the region towards the EOI (right-hand side), which
represents healthy tissue, it appears that the benefits of gating were minimised. Gating
resulted in even more dose smearing towards the EOI into the area representing healthy
tissue, compared to ungated dose delivery.
In Figure 3.18, the dose area histogram for the region representing the surrounding
healthy tissue around the PTV (area not enclosed by 95% isodose), is shown for the resulting
dose distributions just discussed above for gated and ungated delivery sessions under the
influences of baseline drifts of 6mm, 9mm, 12 mm. The static reference (blue) DAH has
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also been added for comparison. All DAHs were evaluated relative to the static reference
distribution, but in this case the area selected as region of interest (OAR) was the area not
enclosed by the 95% isodose level in reference distribution. The larger peak seen for the
static case for doses greater than 80% is because intrafractional motion and baseline drifts
lead to a decrease in the cumulative dose to the PTV (underdose), which results in a decrease
in the PTV area receiving doses less than the prescribed. This means that the area enclosed
by high dose region inside the PTV is smaller, compared to the static case (see dose profiles).
Figure 3.17: Comparison of dose profiles corresponding to un-gated and gated dose distribu-
tion under the effects of 6, 9, 12mm baseline drifts
Dose area histograms show that overall, with respect to the reference dose distribution
and dose values between the 20% and 80% of prescribed dose, the overdosed area outside the
PTV(ref), resulting from simulated drifts of 6, 9, and 12 mm, was decreased with gated beam
delivery by approximately 20.1%, 32.6% and 31.3%, respectively. However, it can also be
observed that gating led to a slightly increase in the area outside PTV(ref) receiving higher
dose levels, i.e. > 80%, compared to un-gated dose delivery, as illustrated in Figure 3.18.
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Figure 3.18: Dose area histogram of the area outside PTV (region outside the 95% isodose
level IDL95%), representing the surrounding healthy tissue.
3.4 Summary
Phantom studies were conducted to investigate the dosimetric effects that intrafractional
motion and baseline drift may have on the dose to the tumour substitute during gated beam
delivery. Film dosimetry was based on dose distributions in the coronal plane through the
centroid the tumour surrogate. Dose area histograms as well as dose profiles were generated
allowing the quantification of the delivered dose to PTV and penumbra widening. Intra-
fractional motion led to an enlarged beam penumbra and hence to less conformal dose
distributions, which resulted in an overall decrease in the cumulative dose to the PTV. Gated
beam delivery improved dose conformity at the expenses of increased delivery times. For an
amplitude-based approach and 38% reference duty cycle, gating allowed a 41% reduction in
dose blurring caused by motion with a reduction of 31% in treatment efficiency. However,
these dosimetric gains were compromised by the effects of baseline drifts, which caused a
shift in dose distribution in addition to increased dose blurring. For instance, for the same
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reference 38% duty cycle, baseline drifts between 3mm to 12 mm led to an increase in dose
blurring by 10% - 70%. Compensation of baseline drift by reducing the gating window was
possible only to a certain extent. Baseline drifts need to be considered during planning
and require larger margins for compensation that intrafractional motion. Unfortunately,
baseline drifts cannot be easily identified by means of 4D computed tomography (CT) for
its integration into treatment planning. This calls for monitoring tumour position during
delivery either by imaging or other means to identify variations in the tumour’s residual
motion within the gating window caused by baseline drifts. Real-time tumour tracking
will potentially address these issues. Previous studies [16] have demonstrated the feasibility
of EPID-based tumour visualisation and its markerless localisation but this has not been
applied to RGRT. A feasibility study for EPID-based verification of tumour position during
gated RT is to be investigated in the next chapter.
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Chapter 4
Tumour Tracking Study
A method for real-time verification of tumour position is required to maximise the poten-
tial benefits of respiratory gated RT (RGRT), which may facilitate the safe reduction of
treatment margins and ultimately dose escalation. RGRT is becoming widely available as a
means for motion compensation of tumours affected by respiration, and is offered by several
manufacturers of medical equipment. Although its benefits have been reported in numerous
studies [23, 24, 25, 51], there are some issues associated with the use of such commercially
available systems, in particular with those that rely on the monitoring of external surrogates
to derive internal tumour position (i.e., optical reflector, pressure belt, spirometer), which
rely on the fact that the correlation between surrogate and actual tumour motion remains
stable over time. However, it has been identified that the degree of such correlation can vary
intra-/interfractionally [45, 46, 54], suggesting that the use of external surrogates alone is
not sufficient for guiding the delivery of gated treatment beams. This calls for the direct
monitoring of tumour position during treatment.
Most of the existing approaches for treatment verification and direct determination of tu-
mour position during gated RT have resorted to using fiducial implants, which are monitored
and tracked by means of either kV fluoroscopy [44] or megavoltage imaging systems [59, 56].
This is accomplished at the cost of increased risk of infection involved with the implant
procedure, and additional exposure of patient to considerable levels of imaging dose. By
the time this work was initiated, reports on methods for imaging and tracking lung tumours
in real-time during gated RT with focus on minimum treatment invasiveness (markerless)
and exposure of the patient to imaging dose, were scarce. In this work a dedicated soft-
ware package, denoted PortalTrack developed at the University of Wuerzburg, was utilised.
PortalTrack is capable of determining tumour position directly in portal images without
implanted fiducial markers using the Megavoltage (MV) treatment beam (exit dose) and the
electronic portal imaging device (EPID). Using PortalTrack and the EPID system only as
image-guidance tool will address issues with regards to the invasiveness of the implant pro-
cedure, while at the same time discarding the need for additional imaging hardware, which
will prevent the additional exposure of patient to imaging dose.
In this work, the suitability and potential of PortalTrack for markerless position verifi-
cation of lung tumours during RGRT is investigated. The issue of discrepancies between
external surrogates and internal tumour motion in RGRT is also addressed. To accomplish
this, it was evaluated whether or not (1) it is feasible to track lung tumours during RGRT
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without markers using PortalTrack, (2) the tracking information is enough to detect subtle
changes in tumour motion within gating window, and (3) whether tumour tracking can po-
tentially improve the accuracy and effectiveness of gated treatment as performed by a third
party gating system.
4.1 Method and Materials
A dedicated software package, denoted PortalTrack, was utilised for real-time imaging and
tumour tracking. PortalTrack was written in Visual Basic (Microsoft Corporation, Redmond,
WA) and it acquires, stores, and displays portal images in real-time. A more detailed
description of the performance of this software has been previously reported by Baier et
al. [50]. Briefly, the software interacts directly with the frame grabber card making use
of the existing dynamic link libraries provided by the manufacture of the EPID system,
and hence manipulate the image acquisition process of the flat panel [50]. PortalTrack is
capable of detecting the tumour position in portal images without using implanted fiducial
markers (markerless tracking). Briefly, the projected trajectory is obtained by defining a
beam specific mask over a representative portal image in which the target has been identified.
This mask serves as reference window, which is instructed to move pixel-wise within a certain
region (search range) over consecutive portal images. An intensity-based root-mean square
difference algorithm is responsible for searching the best matching mask position in every
consecutive portal image of the acquired EPID movie. The details of this process and
feasibility of tracking moving tumours with megavoltage portal imaging have been described
previously in the work by Meyer et al. [16]. Previous studies with PortalTrack have reported
a mean tracking accuracy of 0.36 mm ± 0.12 mm for phantom studies and 1.0 mm ± 1.1
mm for realistic lung tumours during SBRT [39]. The suitability of PortalTrack for tumour
tracking and motion compensation by means of robotic HexaPOD treatment couch has also
been investigated and shown promising capabilities [42].
To investigate the suitability and potential of PortalTrack for the tumour position verifi-
cation during RGRT, EPID movies and the external respiratory signals were synchronously
acquired for the motion phantom during delivery sessions of 200 MUs each. The centroid
of the tumour substitute was placed in the linac isocentre and a 6 MV radiation beam at
0o gantry angle. For simplicity, a square field size (4 cm x 4 cm) was chosen to ensure the
target substitute was always within the beam. EPID movies were acquired at ≈ 2 fps (frames
per second). All deliveries were performed on an Elekta Synergy S (Elekta, Crawley, UK)
equipped with an MV amorphous silicon (a-Si) EPID. Retrospectively, all EPID movies were
loaded into PortalTrack and analysed by simulating gated delivery and tumour tracking for
hypothetical gating windows with varying threshold levels.
4.1.1 Simulation of Gated Delivery
Gated treatments was simulated by manipulating the acquired EPID movies to create inter-
mittent periods of beam-on (gates) and beam-off as the movies were played. To accomplish
this, an amplitude threshold level was set on the external respiratory curve to define a hy-
pothetical/or imaginary gating window in the surrogate space, separating the portion of
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breathing cycle chosen to be encompassed by the gating window, i.e. end-of-exhalation,
from the rest of breathing trace. Any time the external signal falls below the predefined
threshold, it is considered to be within the gating window (beam-on). Furthermore, since
both the external signal and EPID movies were acquired in a synchronous fashion, the portal
images corresponding to the time signal remained within the gating window were selected
to represent periods of beam-on (gate), whereas those that did not to represent periods of
beam-off. Additionally, for the purpose of this study, a new feature was implemented into
PortalTrack, which allowed the handling of intensity fading of portal images. With this
tool, portal images could be either set to retain their default intensity value, i.e. a visible
image, or obscured (completely faded), i.e. a dark image. Subsequently, all frames which
were not inside the gating window, corresponding to beam-off time, were obscured leaving
those corresponding to beam-on only visible. This is illustrated in Figure 4.1
Figure 4.1: Simulation of gated delivery by obscuring the frames which are not inside hypo-
thetical gating window
With the above-mentioned approach, gated treatments with different duty cycles of clin-
ical relevance (15% - 60%) were simulated. The gating window was chosen to encompass
the respiratory signal’s EOE. An amplitude-based gating approach was simulated in the
sense that a fixed gating window was set on external breathing signal, mimicking the use of
commercially available gating systems. The obscuring of frames is analogous to acquiring
images with the electronic portal imaging device during a realistic gated treatment proce-
dure. Moreover, when in cine mode the EPID continuously acquire images even when the
MV beam is turned off (blank images). These blank images are equivalent to those that are
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obscured for the purpose of this study.
4.1.2 EPID Tracking
Tumour tracking was performed during each simulated gated treatment. Thus, only the
frames acquired during beam-on time were available (or visible) to PortalTrack to detect the
positions of the moving target inside the gating window. A representative portal image, with
the target showing less imaging artifacts (high contrast), was selected (see Figure 4.2(b))
for the definition of a reference mask. Based on the shape of the target a reference mask
was defined by drawing an annular contour around the high contrast edges of the target, as
shown in figure 4.2(b). For automatic tracking the mask was moved pixel-wise (with a pixel
equivalent to a resolution of 0.25 mm) within a user-defined search region of 30 pixels in
each direction for any consecutive portal image acquired inside a hypothetical gating window.
The position of the moving tumour substitute is directly determined in each portal images
by the tracking algorithm, which minimised the mean sum of squared differences (MSSD)
of pixels in the current mask position and in the reference mask to find the best matching
position of tracked target, as described by equation 4.1.
MSSD(Iref , Ij) =
1
N− 1
N∑
i = 1
(Bi − Ai)2 (4.1)
where A is the region defined by the reference mask in representative portal image Iref ,
B is the corresponding region over the consecutive portal images, and N corresponds to the
total number of pixels [16]. Absolute values, representing the trajectory determined in pixels
values, were converted into millimeter. All positions detected in portal images were stored
and used to quantify target motion inside the gating window. This study was only concerned
with motion along the SI direction, since it is the predominant direction of motion observed
for tumours in the lung [27, 39].
Figure 4.2: (a) Selection of representative portal image showing the target to be tracked, and
(b) definition of reference mask (right) over the characteristic non-homogeneous edges of the
target.
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4.1.3 Data Analysis
Measurements of the Residual Motion
The residual motion as well as the probability density function (PDF) were used as mea-
sures to quantify target motion inside the gating window and its variability. The residual
motion is the target motion during the time the gate is open (beam-on time) [46, 47, 59],
and its value gives an estimate of the intrafractional variability of tumour motion inside
the gating window. Tracking information was used to determine the residual distribution
(PDFresidual), comprising all the target positions detected inside the gating window. The
range of PDFresidual, measured at 95
thpercentile, gives an estimate of the magnitude of resid-
ual motion within a given gating window. The selection of the 95thpercentile as measure of
residual motion was based on the literature concerning measurements of residual motion by
other group studies [17, 45, 46, 59].
Discrepancies in the Internal/External correlation
Irregularities in the trajectories of tumour substitute were also simulated in order to inves-
tigate their impact on RGRT. As mentioned previously, variations in the internal/external
correlation represents a major limitation to external-based gating techniques. Discrepancies
between the internal and external signal were simulated, in analogy with previous study in
Chapter 3, by keeping the external signal constant while simulating various baseline drifts in
the trajectories of the tumour substitute during simulated gated treatments. Henceforth, all
baseline drifts were simulated digitally in PortalTrack by once again manipulating the EPID
movies. A feature in PortalTrack allowed the user to shift the portal images pixel-wise either
along the longitudinal (y axis) or the lateral (axis) directions depending on the intended di-
rection of drifts. Shifting the frames digitally did not affect the functionality of the tracking
algorithm. Therefore, measurements of residual motion were conducted for both regular and
irregular paths of the tumour substitute. All resulting PDFs(residual) were described in terms
of their standard deviation (SD), mean (m) and range to measure residual motion and its
intrafractional variability.
Determination of Ideal PDFs
Due to the characteristics of the flat panel, the maximum frame rate of image acquisition
approximately 2 frames/sec. Therefore, PortalTrack was limited to acquire information
regarding the target motion inside the gating window every 0.5 sec. To investigate whether
the tracking information was sufficient to quantify residual motion, piecewise cubic Hermite
interpolation was applied to motion data acquired from EPID movies. This allowed to assess
the advantages of having a higher acquisition rate of frames, and thus an increased number
of data points (positions inside the gating window) compared to a lower acquisition rate of
≈ 2 frames/sec.
Data interpolation was applied to all simulated trajectories of the tumour substitute. The
same procedure, as above, was used to determine the residual motion inside equivalent (same
duty cycles) hypothetical gating windows. Interpolated motion data inside a given gating
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window, was interpreted as the true target motion, which represented the ideal probability
density function (PDFideal). The range at 100
th percentile of such ideal PDF constituted the
’true’ residual motion. This value of true residual motion was compared against the value
determined with PortalTrack on the 2 frames/sec movies to evaluate how close PortalTrack
can retrieve reliable information regarding the target motion inside the gating window. All
data analysis was performed using MATLAB R2009b (The MathWorks, Inc., Natick, MA).
4.2 Results and Discussions
4.2.1 Measurements of Residual Motion
The residual motion of the tumour substitute driven by the motion phantom was mea-
sured during simulated gated treatments for 5 hypothetical gating windows with duty cycles
between 15% and 60%. For this section, only motion path 1 of the tumour substitute, rep-
resented by a sinusoidal curve with an amplitude of ≈ 9 mm and cycle length of 4 sec, was
analysed. Figures 4.3(a-b) illustrate the positions of tumour substitute determined with
PortalTrack during two simulated gated treatments with duty cyles of 50% and 25%. An
amplitude threshold level set on the external signal defined the gating window. The shaded
regions represent the beam-on time (gates), whereas the red dots represent the positions of
the target detected by PortalTrack inside the gating window. The two horizontal dashed
lines drawn on the internal signal plots indicate the range of residual motion resulting from
applying 50% and 25% gating duty cycles to external signal, respectively. In addition, the
histograms representing the distribution of target positions obtained during simulated gated
(red histogram) and un-gated deliveries (grey histogram), are also given for each case. The
un-gated distributions corresponds to the whole motion range (peak-to-peak) of the target
(grey trajectories), which may be equivalent to applying a 100% gating duty cycle to exter-
nal signal, representing the maximum magnitude of residual motion. The potential of gated
beam delivery to reduce intrafraction motion is more clearly illustrated by comparing the
un-gated distributions against those determined with PortalTrack (PDFresidual).
Measurements of residual motion based on tracking information showed a reduction of
the substitute tumour motion with gating beam delivery. For duty cycles of 15%, 25%,
35%, 50% and 60% the measured residual motion at the 95th percentile were 1.75 mm, 4.1
mm, 5.11 mm, 8.56 mm and 9.25 mm, whereas the standard deviations of residual PDFs
determined with PortalTrack were 0.77 mm, 1.38 mm, 1.82 mm, 2.65 mm and 3.26 mm,
respectively. Results showed a relationship between residual motion and gating duty cycle,
with a decreasing trend in residual motion as smaller gating duty cycles were applied, as
observed in Figure 4.4(e).
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(a) Target positions detected in the superior-inferior direction (red dots) during simulated gated treat-
ment with 50% dc
(b) Target positions detected in the superior-inferior direction (red dots) during simulated gated treat-
ment with 25% dc
Figure 4.3: Positions of tumour substitute determined with PortalTrack (red dots) during the
time the external signal falls inside the gate (shaded regions) for simulated gated treatments
with duty cycles of 50% (a) and 25% (b), and resulting distribution histograms, PDFresidual,
(red histograms)
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Moreover, a reduction in the standard deviations of the determined PDFsresidual, repre-
senting the spread of detected positions inside the gating window, was also observed. With
gating, the standard deviations of residual PDFs were reduced by 27% - 50%, relative to the
un-gated distribution with 6.57 mm standard deviation. Although these results seem intu-
itively obvious with regard to the functionality of gated delivery, PortalTrack gave an extra
degree of confidence to gated treatment by allowing the direct monitoring of target motion
in the linac beams-eye-view during treatment. This represents a significant improvement
compared to gated treatment procedures conducted in the absence of an image-guided tool
for verification of treatment.
Figure 4.4: Residual motion distribution histograms for applied gating duty cycles of 25%(a),
35%(b), 50%(c) and 60%(d). The residual motion as function of gating duty cycle show a
linear relationship (e).
4.2.2 Variations in Residual Motion
The objective of this section was to investigate the effects irregularities in the target tra-
jectories, as well as discrepancies in the external/internal correlation on residual motion.
Intra-/interfractional variations in both the internal tumour mobility and breathing pat-
terns have been reported in the literature [26, 27, 28, 39, 45, 46]. For instance, the external
signal may drift downwards as the patient relaxes. As a result, clinicians are required to
monitor the external signal during treatment and once a drift is identified the treatment
may be interrupted [17, 26]. However, if there is no information regarding the tumour posi-
tion during treatment there is no way to identify variations in the internal trajectory of the
tumour. Large fluctuations in residual tumour motion have been reported [46, 56]. Even
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at the same external duty cycle the tumour may exhibit more or less residual motion intra-
/interfractionally. The lack of monitoring means uncertainty [17], which may result in gating
errors leading to false negatives and false positives [29, 47].
Baseline drifts of 3 mm and 6mm, which are within the ranges of those found in the
literature regarding the tracking of lung tumours in stereotactic body radiotherapy (± 4
mm) [39], were simulated. Only the internal trajectories of tumour substitute were perturbed
whereas the external signals were kept un-changed through simulated gated treatments. All
drifts were simulated towards the EOE direction of respiration. The effects a regular (path
1) and an irregular exhibiting a baseline drift of ≈ 3 mm (path 2), with a reference 35% dc
gating window, is illustrated in Figure 4.5. Such irregularity led to a systematic shift of exhale
positions, deviating from their intended position, which was defined by the gating window
(the region within the two horizontal dotted lines drawn in the internal signal plot). This
irregularity is reflected in the spread of PDF(residual) in the direction of drift (red histogram),
causing an increase in standard deviation of the residual PDF from 1.93 mm to 2.52 mm
(30% increase) and in residual motion from 5.77 mm to 8.42 mm (46% increase), compared
to gated delivery with same gating duty cycle in the absence of baseline drift. Moreover,
such deviations of the target from reference position could represent incidences of target
underdosage.
It is expected that a larger drift could result in a more significant increase in residual
motion, which in turn could lead to incidences of false positives (beam-on at the wrong
target position [29]), such as in the case shown in Figure 4.6. For this example, a 6 mm
drift resulted in an increase in residual motion up to 11.37 mm with same reference duty
cycle, which constitutes a percentage increase between 36% to 97%, compared to path 1 and
path 2, respectively. This could have adverse effects on accuracy and efficacy of external
based gating. Furthermore, such irregularity would have passed unnoticed in the absence
a verification tool such as PortalTrack in order to detect possible deviations of the target
from reference position, which may not be manifested in the external signal pattern. These
observations are comparable to those pointed out in the work by Nelson et al [56]. Investi-
gators found unexpected tumour motions during gated treatment, which was not reflected
in the analysis of the external signal, leading to significant magnitudes (> 2 cm) of residual
tumour motion.
Overall, baseline drifts were detected and tracked with PortalTrack during simulated
gated deliveries. In Figure 4.7, the residual PDFs determined with PortalTrack, as well as,
their calculated parameters of standard deviation and ranges of residual motion, resulting
from simulated gated treatments with duty cycle of 15%, 25%, 35%, 50% and 60%, are
shown for paths (1-3). The first column corresponds to a regular (path 1) trajectory of
tumour substitute, whereas the second and third columns corresponds to irregular trajec-
tories exhibiting drifts of 3 mm (path 2) and 6mm (path 3). In contrast to a regular path
of tumour substitute, a 3 mm drift led to increases in standard deviation of residual PDFs
from 1.48 mm to 4.11 mm and in residual motion from 5 mm to 13.32 mm, whereas for the
case of 6 mm drift from 2.15 mm to 4.37 mm and from 7.59 mm to 15 mm, respectively. A
correlation between baseline drift and residual motion was observed. Baseline drifts led to
an increase in residual motion by a value approximately equivalent to the magnitude of the
simulated drift.
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(a) Regular trajectory (path 1) of target detected within a 35% gating window
(b) Irregular target trajectory exhibiting baseline drifts ≈a 3 mm (path 2) detected within a 35% gating
window
Figure 4.5: Two examples of target tracking during simulated gated delivery with a 35%
dc reference gating window for a regular (a) and another irregular (b) trajectory of tumour
substitute. A 3mm baseline drift led to deviations in the target’s path from the intended
position.
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Figure 4.6: Motion path of tumour substitute exhibiting a 6 mm baseline drift. Such irregu-
larity leads to significant deviations from target’s intended position, increasing the chances
of marginal miss
Simulations showed that increases in residual motion may be compensated, to a certain
extent, by narrowing the gating window. For instance, for a simulated trajectory exhibiting
a drift of 3 mm the residual motion was reduced by 62.5% with a 15% dc compared to a
larger gating window of 60% dc. Whereas, a reduction in residual motion of about 49% was
only observed for target under the influences of larger 6 mm drift. However, at the expenses
of prolonged delivery times, as demonstrated in previous chapter (Chapter 3, section 3.2.1).
4.2.3 Comparison with Ideal PDFs
This section investigates the trade-offs between faster (ideal) image acquisition and the
current frame rate of the system. The system presented herein offered a frame rate of ≈ 2
frames/sec due to the hardware characteristics of the amorphous silicon flat panel detector,
whereas the time needed by tracking algorithm to find each position (best match) of tracked
object in portal images was on average 0.3 sec ± 0.1 sec, which could be reduced by a factor
of 4 by skipping every second row and column within the search range during the search
for best match, as reported in the work by Wilbert et al. [42]. As a result of this, it was
evaluated whether the tracking information was sufficient to quantify residual motion as well
as other irregularities in the internal target paths that could have been underestimated.
Simulated trajectories obtained from tracking the tumour substitute in EPID movies
were interpolated to 0.05 sec intervals, corresponding to a frame rate of 20 frames/sec. This
rate was roughly similar to the sampling frequency at which the external signal was acquired.
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Figure 4.7: Resulting residual PDFs (PDFresidual) corresponding to motion paths 1 (left
column), path 2 (middle) and path 3 (right column)
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The comparison of ideal PDFs, obtained from interpolated data, against those determined
with PortalTrack (PDFresidual) is illustrated for the three cases (paths 1-3) shown in Figure
4.8. The 95th percentile of PDF(residual) in a 35% duty cycle window served as reference
value of gating efficiency. From this figure, it can be observed that most of the positions
in or near the end-exhale were detected by PortalTrack. Furthermore, exhale positions
were tracked even when the target exhibited baseline drifts, provided that the target moves
within gating window. This is better illustrated by the residual PDF corresponding to
path 1 (regular/no-drift) showing a peak around the end-exhale phase, Overall, the shapes
of residual PDFs resemble those of ideal PDFs for the three cases, with their standard
deviations and calculated values residual motion of residual PDFs differing by 0.01 mm and
0.52 mm, 0.07 mm and 0.8 mm, 0.08 mm and 0.07 mm for path 1, path 2 and path 3,
respectively.
(a) Path 1
(b) Path 2
(c) Path 3
Figure 4.8: Comparison between the position information obtained by PortalTrack (in red)
and interpolated data at 0.02 sec intervals (in black) representing the true target motion
inside the gating window. A reference gating window with 35% dc was used for all simulated
delivery sessions.
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A summary of measured parameters of standard deviation, mean and residual motion
for both residual (PDFresidual) and ideal (PDFideal) position distribution histograms cor-
responding to regular and irregulars trajectories, is given in Table 4.1. For the simulated
gated treatments with hypothetical gating windows of 15%, 25%, 35%, 50% and 60% duty
cycles, the differences between the ’true’ values of residual motion and those determined
with PortalTrack ∆ |PDFideal − PDFresidual| ranged from 0.05 mm to 1.08 mm with a mean
difference of 0.4 mm ± 0.3 mm. Figure 4.9 compares the residual motions measured with
PortalTrack and those representing their true values obtained from interpolated data for
target paths (1-3) and simulated gated deliveries with duty cycle between (15% - 60%). The
shifts in the measurements of residual motion corresponding to path 2 and path 3 relative
the path 1 are explained by the effects of baseline drifts, which led to a systematic shift in
exhale positions and hence in an increase in the residual motion within the gating window.
The magnitude of the shift is proportional to that of the simulated drift. These increases
in residual motion are correlated with increases in the margins that would be required to
compensate for the effects of baseline drifts, in addition to the margins already allocated for
the compensation of residual motion taken into account during treatment planning process
based on 4DCT or a fluoroscopy session. From Figure 4.9 it can be observed that PortalTrack
gives a very close estimate of the true residual motion.
Table 4.1: Comparison of measurements of residual motion and standard deviation of posi-
tion distributions determined with PortalTrack (PDFresidual) and those obtained using inter-
polated data (PDFideal), representing an ideal system capable of faster processing compared
to PortalTrack. For all the PDFs the mean (m) and standard deviation (m) are given.
Path DC PDFm±SD (mm) PDF95thprctile (mm)
# % PortalTrack Ideal PortalTrack Ideal ∆
∣∣∣95thprctile∣∣∣
15 0.80 ± 0.77 0.89 ± 0.84 1.75 2.44 0.69
25 1.50 ± 1.38 1.51 ± 1.38 4.09 4.14 0.05
1 35 2.02 ± 1.93 2.19 ± 1.93 5.77 5.71 0.06
50 3.06 ± 2.64 3.17 ± 2.72 7.75 8.12 0.35
60 3.87 ± 3.26 3.82 ± 3.25 9.25 9.68 0.43
15 0.01 ± 1.48 -0.04 ± 1.43 5 5.22 0.22
25 0.73 ± 2.03 0.67 ± 1.95 6.79 7.12 0.33
2 35 1.29 ± 2.52 1.35 ± 2.45 8.42 8.68 0.25
50 2.09 ± 2.99 2.32 ± 3.19 9.92 11.01 1.07
60 3.52 ± 4.11 2.96 ± 3.70 13.32 12.53 -0.79
15 -1.27 ± 2.15 -1.08 ± 2.2 7.59 8.19 0.6
25 -0.06 ± 2.79 -0.30 ± 2.65 9.74 9.83 0.09
3 35 0.41 ± 3.18 0.37 ± 3.1 11.37 11.44 0.07
50 1.39 ± 3.77 1.42 ± 3.78 13.64 13.91 0.27
60 2.29 ± 4.37 2.16 ± 4.32 15 15.73 0.73
0.41 ± 0.31
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Figure 4.9: Comparison of determined residual motions with PortalTrack and their ideal
values for motion path 1nodrift (data points in red/light red), path 23mmdrift (data points in
black/gray) and path 36mmdrift (data points in blue/light blue).
4.3 Summary
This study evaluated the suitability of a clinical tool for real-time tumour position verification
during gated beam delivery. The approach is based on the direct imaging and tracking of
moving targets in portal images, acquired during beam-on time, without the aid of implanted
markers and using the therapeutic MV treatment beam. Under the simulation of gated beam
delivery, different gating duty cycles were applied and the target residual motion during
beam-on time measured. Simulations showed that PortalTrack is capable of measuring target
motion within the gating window. Measurements of residual motion showed a relationship
between gating duty cycle and residual motion, with smaller duty cycles leading to less
residual motion inside the gating window. Although such results supported the functionality
of gated beam delivery, whose main goal is to reduce target motion within the treatment
portal, PortalTrack gave added confidence in the simulated treatment procedure since it
allowed for the direct monitoring of the target motion during dose delivery.
Investigations of the effects of baseline drifts on residual motion indicated a clear cor-
relation between both parameters. Baseline drifts led to an increase in residual motion by
a factor approximately equivalent to the magnitude of exhibited drift. Compensating for
baseline drifts would require larger margins than those initially assigned during treatment
planning based motion characteristics, i.e. peak-to-peak motion amplitude, of the tumour
acquire through fluoroscopy or 4DCT.
Tracking information was sufficient to quantify residual motion. The relative slow frame
rate of the tracking system did not constitute a limitation when estimating values of residual
motion. Residual motion determined with PortalTrack was very close to the true residual
motion, with a mean difference of 0.41 mm ± 0.31 mm for all simulated trajectories and
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gated treatments. Furthermore, tracking information showed that variation in residual mo-
tion, such as those resulting from baseline drifts, may be compensated by adjusting the
gating window, however only to a certain extent, as there may be cases in which the resid-
ual motion is so large that it cannot be dealt with by only narrowing the gating window.
Such tracking information could potentially be used to update/validate the degree of exter-
nal/internal correlation, using the tracking information as the true tumour signal, to correct
possible variations in the external signal which may arise during treatment [47]. Alterna-
tively, tracking information can be used to adjust or adapt the gating window to compensate
for variations in residual motion, as suggested by Aristophanous et al. [17].
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Chapter 5
Clinical Study
In this section, the feasibility of the approach presented in the previous chapter was evaluated
by means of a clinical case study. The objective of this study was not to quantitatively prove
or disprove the degree of internal/external correlation, but to investigate the possibility of
treatment verification with PortalTrack which may improve the safety and effectiveness of
external based gated RT.
5.1 Method and Materials
Data Acquisition
The approach for tumour position verification was retrospectively evaluated based on patient
data collected at the Department of Radiation Oncology, University of Wuerzburg. The
subject was a lung cancer patient treated with stereotactic body radiotherapy (SBRT) with
a prescribed dose of 57.6 Gy delivered over 3 fractions using 6 fields per fraction. During
treatment delivery, EPID movies were acquired by megavoltage imaging of the treatment
beam, producing a projection of the tumour onto the plane of the electronic portal imaging
device (EPID) (see Figure 5.1). The tumour position is determined in portal images of
acquired EPID movies, which represented the internal signal. At the same time, the three
dimensional (3D) breathing motion of the abdomen of the patient was recorded by tracking
an optical marker placed on the abdomen of the patient with an infrared camera (Polaris,
NDI, Waterloo, Ontario, Canada), referred to as external signal (see Figure 2.5). Overall,
this resulted in the synchronised acquisition of both internal and external datasets during
treatment. For this study only the one dimensional (1D) anterior-posterior (AP) component
of the external signal was used for the simulation of gated treatment, hence mimicking the
use of commercially available gating systems. Moreover, only tumour motion in the superior-
inferior (SI) direction was studied since this is the predominant direction of motion observed
for tumours in the lung [27, 39].
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Figure 5.1: Display window from PortalTrack showing a lung tumour being tracked in the
beam’s-eye-view (left panel), and corresponding DRR (right panel) used for the definition of
the search mask (green annular contour).
Gating Window Definition
For the simulation of gated treatment both external and internal signals were first analysed
over a treatment observation time, corresponding to the first 30 seconds of treatment, to
define gating parameters, i.e. gating duty cycle, whether to gate at EOE or EOI. In a
real gating procedure, such parameters are defined based on the information provided by
fluoroscopy or 4DCT imaging of the patient. During observation time an external amplitude
(EA) and an end-exhale baseline (Ext. baseline) were determined by taking the average of all
the peak-to-peak amplitudes and end-exhale positions of the external signal. A fixed gating
window was defined by the distance between the end-exhale baseline and a reference 35%
amplitude threshold level, referred to as external upper limit (Ext. UL), set on the external
respiratory signal (red horizontal line), as illustrated in figure 5.2(a). The choice of the
reference 35% duty cycle, resulted in ≈ 6 mm residual tumour motion, which was assumed
to be clinically allowed for the simulation of gated treatment as indicated in the literatute
[18, 29]. The gating window remained unchanged (fixed) throughtout fraction delivery (6
fields), mimicking an amplitude-based gating approach with fixed gating window. Obscuring
of portal images, which were not in inside the gating window, was performed as discussed in
the previous chapter.
Permitted Range of Residual Tumour Motion
Additionally, a reference frame by which possible deviations of tumour from its intended po-
sition could be judged, i.e. permitted range of residual motion, was defined during treatment
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observation time. As result of the 35% dc gating window set on the external signal, it was
assummed that no more than 6 mm residual motion was allowed. During pre-treatment time
the internal signal, which was available over the entire time, was retrospectively analysed in
the same fashion as the external signal. An internal tumour motion amplitude (IA) of 16.7
mm ± 2.9 mm was determined by taking the average peak-to-peak motion amplitude all
breathing cycles found over the observation time. An internal baseline (Int. baseline) was
also defined by taking the average of all end-exhale tumour positions found over treatment
observation time. A transformation factor (TF), the ratio of external amplitude (EA) to
internal amplitude (IA), allowed to translate the external to internal amplitude and vice
versa. The permitted range of residual motion was defined by the distance between the
internal baseline (Int. baseline) and the internal upper limit (Int. UL), which was calcu-
lated by dividing the reference gating window (35% of EA) by TF. Defining this permitted
range of residual motion will allow the appreciation of variations in the internal mobility
of the tumour, as well as in the reproducibility of tumour exhale positions, relative to the
planned position, which may arise during treatment. In an idealised gated treatment the
exhale positions should be fairly stable and fall within this range to ensure adequate tumour
coverage.
Figure 5.2 shows all the parameters defined for both internal and external signals over pre-
treatment time. On the external signal plot the gating window is defined by Ext. UL (35%
amplitude level in red) and Ext. baseline (Figure 5.2 (a)), whereas on the internal signal plot
the permitted range of residual motion by the Int. UL and Int. baseline (black horizontal
dashed line) (Figure 5.2 (b)). The red dots represent the tumour positions obtained from
tracking the tumour in portal images during beam-on time.
Figure 5.2: Definition of gating window on external respiratory signal (a), and permitted
range of residual motion (b) during pre-treatment observation time (first 30 sec of treatment).
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Tumour Tracking
The definition of the reference mask for tumor tracking was based on the digitally recon-
structed radiographs (DRR) generated for each beam during treatment planning. This was
conducted in order to help identify the tumour in the reference image to ensure that the
tracking algorithm follows the actual tumour and not projections of other anatomical regions
[42]. The contour of the macroscopic tumour was overlaid and stored with the DRR. Both the
EPID movies and DRRs were loaded into PortalTrack for simulation of gated treatment and
tumour tracking. From each EPID movie a representative portal image, in a corresponding
phase of the breathing relative to the DRR, was selected for mask definition. The reference
mask was drawn by retracing the tumour contour in DRR and at the same time drawing
the reference mask over the representative portal image. In some cases, a characteristic
nonhomogeneous part of the tumour visible in representative portal was sufficient for mask
definition avoiding the need to encompass the whole tumour, as shown in Figure 5.3. All
pixel values within the defined reference mask were stored. As in the previous chapter, the
mask was instructed to move pixel-wise, relative to the previous frame over a search range
of 30 pixels in each direction. The tumour was tracked in portal images during simulated
gated treatment and determined positions were stored to determine residual PDFs.
Figure 5.3: a) Digitally reconstructed radiograph (DRR) showing the tumour and CTV. (b)
Representative portal in corresponding phase of breathing relative to DRR, and (c) definition
of reference mask based on macroscopic tumour contour defined on DRR.
Tumour Position Verification
For this study, the residual motion metric was based on the work by Berbeco et al. [59], by
calculating r(residual), which is the difference between each gated data point (tumour position
determined in each portal image along superior-inferior direction), y(i), and the daily average
gated position, y(daily,ave), which is the average tumour position obtained by tracking the
tumour in all portal images acquired during beam-on time for the fields in one fraction, as
shown by equation (5.1). Doing this, allowed one to factor out the interfractional (day-to-
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day) error components when calculating the residual tumour motion during fraction delivery,
thus highlighting possible intrafractional (beam-to-beam) variations in residual motion for
a given day.
r(residual) = (y(i) − y(ave)) (5.1)
This difference (r(residual)) formed a residual motion distribution histogram (PDFresidual)
comprising all target positions detected inside the gating window. For each beam, their
corresponding residual distribution histograms (PDFresidual) were described in terms of their
standard deviations and 95th percentiles. Furthermore, deviations in the end-of-exhale tu-
mour positions, which crossed downwards pass the predefined internal baseline (Int. base-
line), were measured to give an estimate of the magnitude of exhale fluctuation, as suggested
in the work of Nishioka et al. [26].
5.2 Results and Discussion
A total of 386 portal images were acquired during fraction delivery corresponding to treat-
ment fields (1-6) at gantry angles 240o, 195o, 285o, 350o, 130o and 150o, respectively. Sim-
ulations showed that tumour motion can be monitored and tracked during RGRT with
PortalTrack. In figure 5.4 and 5.5, both the external, guiding the onset of the gates, and the
internal, tumour positions detected during beam-one, movement plots are illustrated. For
each beam, the gating window is drawn on the respiratory signal, which remained constant
throughout all six fields. The shaded regions represent the time during which the gate was
open. At the instance when the respiratory signal falls in the gate, tumour position is ob-
tained from tracking tumour in portal images (red dots). In addition, the resulting residual
motion distribution histograms (red histograms) are given, representing the distribution of
all tumour positions determined with PortalTrack during beam-on time (PDFresidual). Fur-
thermore, the tumour trajectories obtained without any control for respiration (un-gated
delivery), shown in the background (gray dotted path) of each internal signal plot, as well
as corresponding histograms (gray histograms) are also included for two reasons: (i) to
highlight the possible occurrence of false negatives (beam off while tumour is inside gating
window) and false positive (beam on while the tumour is outside gating window), which may
have arisen from changes in the internal/external correlation during treatment; and (ii) to
use tracking information to evaluate the efficacy of gated delivery to reduce interfractional
tumour motion in both the absence or presence of possible intrafractional variations during
treatment.
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(a) Beam 1 (Gantry 240o)
(b) Beam 2 (Gantry 195o)
Figure 5.4: Fraction one beam 1-2
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(a) Beam 3 (Gantry 285o)
(b) Beam 4 (Gantry 350o)
(c) Beam 5 (Gantry 130o)
(d) Beam 6 (Gantry 150o)
Figure 5.5: Fraction one beam 3-6
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Baseline drifts as well as sudden cycle-to-cycle irregularities in the end-of-exhale tumour
positions were detected and quantified. It was observed that such irregularities led to con-
siderable variations in residual motion, which may in turn result in marginal miss. By
inspecting both synchronised external/internal movement plots for beams (1-6), it can be
seen that in some time intervals the respiratory patterns behaved in an irregular manner,
exhibiting amplitude variations, baseline drifts, as well as sudden (cycle-to-cycle) variations
in exhale positions. Such variations made it difficult to consistently and accurately capture
the exhale positions to guide the gating of treatment beams. Tumour tracking information
showed that in most cases the patterns exhibited by the external signal were translated into
internal tumour movements detected during beam-on time. Maximum detected fluctuations
of the exhale tumour positions ranged from 1.35 mm to 6.67 mm for fields (1-6), as shown
in Table 5.1.
Table 5.1: Measured residual motion at 95thpercentile and standard deviations (SD) of
PDFsresidual determined with PortalTrack throughout fraction delivery. ∆residual represents
the percentage difference between measured and clinically assumed value of residual motion
Beam PDFresidual ∆residual Max. exhale
# SD (mm) 95% range (mm) |measured− allowed| (%) fluctuation (mm)
1 2.5 8.7 49 2.5
2 2.9 10.5 80 4.3
3 4.9 15.9 171 2.4
4 2.4 8.1 38 1.3
5 3.0 9.4 62 6.6
6 2.9 9.4 61 2.4
5.2.1 Intrafraction Variations in Residual Motion
Table 5.1 gives a summary of calculated parameters for beams (1-6). The standard devia-
tions of residual motion distribution histograms (PDFresidual) ranged from 2.4 to 4.9 mm,
with beam 4 exhibiting the smallest and beam 3 the largest deviation. The measured resid-
ual motion measured at 95thpercentile ranged from 8.1 to 15.9 mm, which constituted a
percentage difference (increase) in residual motion between 38% to 171%, relative to the
clinically allowed value of ≈ 6 mm. Large fluctuations in residual motion are observed from
beam-to-beam. There was a decrease of 49% between beam 3 and beam 4 and then a gradual
leveling through the remaining fields. It is interesting to note that beam 3 and beam 4 also
represented the maximum and minimum measured values of residual motion. Taking a closer
look at the external/internal signals for beam 3 (gantry angle 285o), it can be observed that
external signal exhibited baseline drifts, which resulted in longer gates/beam-on time (wider
shaded regions) as the signal shifted downwards. Subsequently, a longer gate means that a
higher percentage of the tumour motion amplitude is allowed to move within the treatment
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portal. This is reflected in the spread of tumour positions (red dots) beyond the defined
range of permitted residual motion (towards the inhale phase of respiration), which in turn
is manifested by the increase in the range of PDFresidual (red histogram), and hence residual
motion. The clinical implications from this would be that if small margins are designed
during the process of treatment planning to encompass the PTV region, comprised by CTV
and assummed permitted range of residual motion (≈ 6 mm), with a given isodose level (i.e.
95% isodose), the tumour will move away from high dose region, leading to a poor tumour
coverage, and possibly marginal miss.
It is worth noting that for the case of beam 3, such high measured magnitude of residual
tumour motion is mostly due to variation in the external respiratory pattern and represents
a worst case scenario of gated treatment, which is included in this study for comparison
purposes. In a realistic treatment procedure with an external-based gating system the treat-
ment would have been interrupted once the drift was identified by monitoring the patient’s
respiratory trace during treatment. Breath couching would have avoided this also by means
of either audio instructions or visual feedbacks with the attempt to maintain a reproducible
breathing pattern during dose delivery [29]. Tracking information showed that the internal
tumour paths during beam-on time seemed to hardly resemble the motion characteristics
exhibited by the external signal. For this case, it is observed that most of end-of-exhale
tumour positions (10 out 12) were detected within the assumed permitted range of residual
motion, whereas external signal exhibited baseline drifts, shifting downwards (posteriorly)
for the first 11 seconds and then anteriorly for the rest of the delivery. This represents a
typical example of degraded internal/external correlation, which constitutes a major limiting
factor to the success of external-based gating techniques that lack an image-guided tool for
treatment verification, as noted in the literature [18, 26, 28, 29, 45, 47, 54]. However, the
importance of PortalTrack is that tumour tracking information can be used to validate the
internal/external correlation to update or readjust the gating window.
Furthermore, by comparing both un-gated and gated distributions, it can be observed
that with gated delivery the standard deviations of tumour positions were reduced by 21.3%
- 61.3%, compared to the case in which no control for respiration was performed. The distri-
bution of tumour motion in the SI direction for the combination of the resulting PDFresidual
correponding to all the six fields is shown in Figure 5.6. The distributions has its mean at
zero, which representes the daily average tumour position. The asymmetry of the distri-
bution is explained by the presence of the above-mentioned irregularies taking place during
simulated treatment. The skew of the distribution towards the inhale direction (to the right
side of the distribution) is mostly attributed to the effects of baseline drifts observed dur-
ing dose delivery for beams (3-5). The 95th percentile of this distribution, which indicates
the limit within which 95% of the data points (detected tumour positions inside the gating
window throughout fraction delivery) are located, is 15.9 mm as opposed to 6 mm. Fur-
thermore, assuming a peak-to-peak tumour motion amplitude of ≈ 16.7 mm, as determined
during treatment observation time (method section), it shows that gating reduced intrafrac-
tion motion by roughly 5% of its magnitude that would otherwise result without any control
for respiration (un-gated). This is in agreement with the work by Korreman et al [45], in
which it was found that even with gating the reduction in the mean tumour motion was low
(6%), mostly due to baseline drifts and variations in the internal/external correlation.
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Figure 5.6: The intrafractional superior inferior (SI) tumour displacement detected in each
of the 336 images acquired during simulated gated treatment
Detection of False Positive/Negatives
The detection of incidences of false positives, which are of more clinical concern since more
dose would be given to healthy tissue [29, 47, 54], can be represented by those tumour
positions detected distantly away from defined permitted range of residual motion. In other
words, finding the tumour outside the permitted range meant that the tumour was located
outside the high dose region, or even outside of the field in the case of those positions with
significant deviations from permitted range. This will be the case provided that only 6
mm residual motion was taking into account for the purpose of treatment planning based
on a 35% duty cycle for gated treatment. For example, in the case of beam 5 (breathing
cycle 1), detected tumour positions 1-3 (end-exhalation) would represent cases in which the
treatment portal was irradiated without having the tumour within the beam’s-eye-view. This
may be also observed in beam 2 (breathing cycles 5-6), beam 3 (cycles 1-8) and henceforth.
These observations would have been better illustrated provided that a real gated treatment
procedure was performed using small treatment margins designed during treatment planning
to explicitly compensate for the clinically allowed residual motion (≈ 6 mm). This represents
a limitation in the study since gated treatment was simulated, patient was treated with SBRT
using an ITV concept encompassing the whole tumour motion range.
On the other hand, the appreciations of false negatives (beam off at the right target
position) from these simulations are difficult due to the fact the external signal directed
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the onset of the gates, which means that no portal images were available to verify if the
tumour was within the treatment portal. To highlight the presence of such effects the whole
motion range of tumour trajectories, representing un-gated treatment, were added in the
background (gray dashed paths) of each internal signal plot. Beam 2 showed the most cases
of false negatives, which in some cases the exhale positions of external signal did not fall
within gating window, whereas the tumour did. In a real clinical procedure this would have
prolonged the treatment.
5.2.2 Margin Determination
In an idealised gated treatment, the treatment scenario should mimic the scenario considered
during treatment planning [30]. Therefore, if the tumour coverage is to be kept constant
throughout the course of treatment, the residual tumour motion should be kept constant and
within the range of residual motion taken into account during treatment planning process.
Subsequently, tracking information was utilised to retrospectively quantify a margin surro-
gate required to compensate for variations in residual motion for each beam and maintain
tumour coverage. To accomplish this, the measured (95th range) and clinically allowed (per-
mitted movements range) values of residual motion were compared. The distances between
the internal baseline and the 5thpercentile, and between the internal upper limit and the 95th
percentile of a distribution were used as measures to quantify adequate margins magnitudes
in both exhalation and inhalation directions.
Table 5.2 gives a summary of calculated parameters for beams (1-6). The distances
between the 5th percentile and internal baseline ranged from 0.2 to 7.6 mm, whereas between
the 95th percentile and internal upper limit from 0.8 to 4.1 mm. Assuming that the range of
permitted tumour movements is enclosed by the 95% isodose, and a homogeneous dose to
tumour is wanted, the margins must be increased by 1.2 mm, 4.1 mm, 2.4 mm, 0.8 mm, 3.9
mm and 2.1 mm in the exhalation direction, and by 1.6 mm, 0.6 mm, 7.6 mm, 1.5 mm, 0.2
mm and 1.5 mm in inhalation direction for beams (1-6), respectively.
Table 5.2: The standard deviation of residual distributions and determined margin surrogates
for fields 1-6. For each PDFresidual the mean (m) and standard deviation (SD)determined
tumour positions are given.
Beam PDFresidual distance Int. baseline distance Int. UL
# m ± SD (mm) to 5thpercentile (mm) to 95thpercentile (mm)
1 -5.8 ± 2.6 1.2 1.6
2 -7.5 ± 2.9 4.1 0.6
3 -3.9 ± 4.9 2.4 7.6
4 -5.5 ± 2.5 0.8 1.5
5 -6.7 ± 3.0 3.9 0.2
6 -6.8 ± 2.9 2.1 1.5
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5.3 Summary
The feasibility of markerless tracking lung tumours for the verification of respiratory gated
treatment was investigated with a case study. Gated treatment was simulated based on mo-
tion data obtained from a lung patient that underwent stereotactic body radiotherapy, from
which both EPID movies and the external respiratory signal were synchronously acquired.
EPID movies were retrospectively analysed in PortalTrack by simulating gated delivery and
tumour tracking. The external signal directed the onset of the gates and the tumour was
directly tracked in portal images acquired during beam-on time.
Simulations showed that tumour motion can be monitored and tracked during respiratory
gated RT. PortalTrack was able to quantify the residual tumour motion as well as it’s vari-
ations. Measurements of residual motion showed that large fluctuations in residual motion
can occur intrafractionally. Irregularities in the internal tumour trajectories, such as baseline
drifts and sudden cycle-to-cycle variations in the exhale tumour positions were detected and
quantified within the predefined gating window. Such irregularities may lead to considerable
variations in residual motion, which may in turn result in poor tumour coverage and in some
cases even in marginal miss if the tumour residual motion is too large.
An evaluation of the internal tumour positions detected during beam-on time with Por-
talTrack showed that the external-based gating alone is not sufficient for precise gated lung
treatment. There were incidences in which the pattern observed on the external signal were
not reflected on true tumour positions detected within the gating window. A verification
system is required in which the respiratory tumour motion can be imaged and quantified to
the extent that a baseline (mean tumour position or exhale position) can be identified or
established [45]. As suggested by Engelsman [34], it is more relevant to compensate for base-
line drifts as they require larger margins than those required to compensate for breathing
induced motion. Portaltrack has shown potential to detect baseline drifts. Information from
PortalTrack may be used for treatment verification or the adaptation of the gating window
such as reported in a recent work by Aristophanus et al [17]. Another direction would be
to use tracking information for the adaptation of the treatment couch to correct for baseline
drifts [42].
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Chapter 6
Concluding Remarks
6.1 Summary
This thesis investigated the potential of RGRT to compensate for the effects of respiration
induced motion and the suitability of real-time tracking for tumour position verification
during treatment. Results have indicated that gated beam delivery for treating mobile
tumours in the lung is advantageous, although its benefits can be further improved with
the aid of a treatment verification tool. Dynamic phantom studies showed that RGRT has
the potential to mitigate the effects of intrafractional tumour motion on dose distributions,
reducing dose blurring effects by enabling steeper dose gradients, which led to improved dose
conformity. Dose delivery in the presence of intrafractional motion without any compensation
for respiration degraded dose conformity, enlarging the beam penumbra by 121% compared to
dose delivery in absence of intrafractional motion. Conversely, gating allowed the reduction
in dose blurring by 28% - 46% with gating duty cycle between 12% dc - 75% dc. The
clinical significance of these findings are that decreasing dose blurring effects with gating
leads to sharper dose distributions, thus resulting in more dose being delived to the PTV
while sparing more healthy surrounding tissue or other OAR which may be in the close
proximity to high dose gradient, i.e. heart. It was observed that reducing the duty cycle led
to dose distribution that resembled those of the static distribution, however, suboptimal in
terms of treatment efficiency.
In real practice, the use of external sensors as surrogates for internal tumour motion may
be a source of uncertainties. It should not be considered a priori that the correlation be-
tween external signal and internal tumour mobility will remain stable throughout treatment.
In fact, in the case of respiration such assumption is difficult make since different driving
mechanisms, i.e., diaphragm, intercostal muscles [18] are involved during respiratory activity.
Therefore, it was of interest to test the performance of the gating system under the influences
of discrepancies in external/internal correlation as well as irregular tumour paths. Results
showed that the dosimetric benefits of gated delivery were overshadowed by the influences
of baseline drifts during dose delivery. Baseline drifts resulted in the systematic deviation of
tumour position from planned position, leading to a shift in dose distributions in addition
to increased dose blurring. For a reference gating window with 38% dc, baseline drifts of 3
mm to 12 mm led to an increase in dose blurring by 10% - 70%. Moreover, compensating
for such irregularities by only adjusting the gating window proved to be limited. The clin-
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ical implications of baseline drifts are that eventhough the tumour motion amplitude may
be small, the systematic shift in its mean motion path would required larger margins for
compensation. Baseline drifts can not easily be identified by means of 4DCT for its integra-
tion into treatment planning process, which may have even more detrimental consequences
in terms of healthy tissue toxicity when smaller field sizes are used such as in the case of
RGRT. More importantly, such drift would be unnoticed unless tumour motion is directly
monitor during dose delivery. Real-time verification of the tumour position is essential to
maximise the potential benefits of RGRT.
The suitability of PortalTrack for the verification of RGRT was investigated in simulations
of gated treatment using the motion phantom, and demonstrated its feasibility with a clini-
cal case study. The results showed that it is possible to determine and track tumor motion
and variability during RGRT. During treatment the tumour was visualised in the beam’s eye
views and its residual motion as well as deviations from intended position (gating window)
measured. Larger irregularities in tumour trajectories as well as in the external respiratory
patterns of the patient were observed, which further justified the need for real-time verifi-
cation during treatment. Measurements of residual motion ranged between 8.1 mm to 15.9
mm, which constituted a relative difference of 38% - 171% compared to the allowed residual
motion of 6 mm, with the major part of these discrepancies arising from baseline drifts and
sudden fluctuations of the exhale tumour positions inside the gating window. These results
are comparable to those reported in the work of Berbeco et al. [46]. Investigators assessed
the validity of external/internal correlation assumption of external-based gating, reporting
intrafractional (beam-to-beam) variations in residual motion > 300%. Exhale fluctuations
up to 6.7 mm were observed. Recently, Nishioka et al. [26] reported exhale fluctuations up
to 12.7 mm for cohort group of 12 lung cancer patients using the real-time tumour tracking
(RTRT) system. The clinical significance of the results coming from this thesis is that if
a patient is to be treated with gating under free breathing, with the gating window set to
encompass the exhalation portion of the breathing cycle, which is commonly done in clinical
procedures, it is important to be aware that exhale positions may fluctuate. However, future
work is required, involving more clinical data, to further support these arguments.
Simulations of gated treatment resulted in the loss of motion data that could have oth-
erwise been used to determine residual PDFs and hence altered their distributions. For the
phantom studies, all the EPID movies were acquired during the delivery of 200 MUs, which
resulted in a certain number of breathing cycles during whole dose delivery. If gated beam
delivery had been performed, delivery times would have been prolonged depending on the
duty cycle applied, resulting in more breathing cycles recorded during EPID movies acqui-
sition. Conversely, during simulations of gated treatment delivery times were not prolonged
and the frames which were not inside the gating window were only obscured and discarded,
leaving only few breathing cycles and hence less data available for tumour tracking and
determination of PDFs.
Evaluations of EPID moves were limited to detecting baseline drifts and other irregu-
larities during beam-on time only, whose magnitudes could have been under estimated in
case the irregularity lasted longer than the gate, moving outside the gating window during
beam-off. Moreover, in the context of RGRT it seems to be more appropriate to refer to
baseline drifts as systematic changes of exhale positions [26, 30], which can be quantified by
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measuring their fluctuations relative to gating window. Figure 5.5 (b) shows the SI tumour
position detected inside the gating window where a drift in exhale tumour position of about
9.26 mm was observed during beam-on time. However, this drift extended over 13 mm when
non-gated delivery was considered. Moreover, EPID movies only provided 2D projections of
the tumour in the plane perpendicular to central beam axis, limiting to detect intrabeam
irregularities only, in fact, it is expected interbeam irregularities to be of larger magnitudes
compared to intrabeam when considering the 3D motion of lung tumours and associated
irregularities.
6.2 Future Work
An important aspect for bringing the present approach into the clinical routine is the feasi-
bility of the tracking process with real tumours. The approach presented herein showed to
be useful with a clinical case in which the tumour could be identified and tracked in portal
images. This clinical case was intentionally selected because of the high visibility of tumour
in portal images. However, the continuous tumour monitoring in portal images may not be
feasible in some cases due to poor image contrast. There is still work to be done in terms of
improving image quality. Alternatively, the makerless tracking process in EPID movies could
be improved with the aid external respiratory signal combined with mathematical models of
the correlation between the abdominal motion and tumour motion as suggested in a recent
study by Wilson and Meyer [60].
Besides real-time tumour localisation, prompt linac response to the gating signal is re-
quired for the success of RGRT [29]. In this work, an immediate response of the linac was
assumed during gated treatment simulations. This could have contributed to a non-negligible
uncertainty when selecting portal images to either be obscured or remain visible. In a fu-
ture work, it would be worth integrating the latency of the response to the gating signal
during simulations, based on the mechanical characteristics of the linear accelerator, and
evaluate the effect on residual PDFs. Furthermore, this study mainly focused on detecting
baseline drifts and exhale fluctuations leaving phase shifts (also referred to as time shift [54])
between the external and internal signals unattended. Detecting such shifts are crucial to
validate/update the external/internal correlation. An analysis of the correlation between the
external respiratory signal and the tumour trajectories detected inside the gating window
with PortalTrack could be addressed in a future work.
6.3 Conclusions
The need for a verification system is of utmost importance in the safe implementation of
external-based gating to ensure that tumour motion inside the gating window is reproducible
and enable corrections in case discrepancies arise throughout the course of treatment. Sim-
ulations showed that by making use of standard components of linear accelerator and a
cost-effective solution such as PortalTrack the effectiveness of commercially available gating
system could be improved. One major goal was to investigate whether tracking informa-
tion was suitable/sufficient to quantify the residual motion as well as other systematic and
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un-expected fluctuations in the internal tumour trajectories inside the gating window, with
the process limited by the acquisition rate of portal images at approximately 2 frames/sec.
Comparisons of measurements of residual motion determined with PortalTrack and that of
a more ideal system, with an acquisition rate of 20 Hz, showed differences ranging from 0.1
mm to 1.1 mm and a mean of 0.4 mm ± 0.3 mm for all the simulated trajectories. This
indicates that the main characteristics of the tumour trajectories inside the gating window
were preserved at sampling rate of 2Hz and that PortalTrack gave a close estimate of the
true residual motion. Although it is obvious that a sampling rate of ≈ 2 Hz could affect
the accuracy of detecting sudden tumour positions that may take place between to sam-
pling points, gated treatments are normally planned to encompass the more stable end-of-
exhalation phase of respiration, where the tumour is expected to spend longer time. Results
indicated that PortalTrack detected and tracked exhale tumour positions and fluctuations
satisfactorily. PortalTrack has shown great potential for the verification of tumour position
during RGRT and the tracking information could possibly be used for adaptive treatment
delivery procedures for the compensation of respiration and variability.
75
Acknowledgment
First of all I would like to thank Dr. Juergen Meyer for his supervision, guidance, valuable
discussions, and specially for inspiring me with the subject regarding the management of res-
piratory motion in radiation therapy. I also greatly appreciate being given the opportunity
to meet and work together with people undertaking cutting edge research on the subject. I
would like to thank Dr. Florian Cremers, the Chief Medical Physicist of University Medi-
cal Centre Hamburg-Eppendorf (UKE) in Germany, for giving the opportunity to join the
medical physics group and work on my research project alongside a multidisciplinary team.
Also for making sure that I had all the required resources available for the realisation of this
research work.
I would like to thank Medical Physics Expert, Mr. Kurt Baier from the University of
Wuerzburg, Germany, for letting me work with his fascinating tracking software, support
with upgrades and implementation of new features, as well as welcoming hospitality in
Wuerzburg. I would like to thank Dr. Juergen Wilbert and Dr. Anne Richter, also from
the University of Wuerzburg, for providing me with clinical data. I would like to thank
Volker Platz from UKE for his support, discussions and for always making sure that I had
an accelerator available for measurements, as well as letting me spend all those hours needed
to learn the operation and use of the gating system. I would also like to thank Dr. Bern
Bobmann from UKE for the feedbacks on this manuscript. I would like to thank Rene
Werner, from the University of Luebeck in Germany, for his support with Matlab routines. I
would also like to thank Lukas Henze for the friendly company at the office. Finally, I would
like to thank my wife for her support in any possible way throughout all this work.
76
Bibliography
[1] E Brambilla, W D Travis, T V Colby, B Corrin, Y Shimosato: The new World Health
Organisation classification of lung tumours. European Respiratory Journal, 18: 1059-
1068, 2001
[2] A Jemal, F Bray, J Ferlay, E Ward, D Forman: Global Cancer Statistics. CA: A Cancer
Journal for Clinicians, 61(2):69-90, 2011
[3] S D Cox, J Y Chang, R Komaki: Image-Guided Radiotherapy of Lung Cancer, Informa
Healthcare USA, Inc., 52 Vancerbilt Avenue, New York, NY 10017, 2008.
[4] T Bortfeld, R Schmidt-Ullrich, W De Neve, D E Wazer: Image-Guided IMRT, Springer-
Verlang Berlin Heildergerg, 2006.
[5] W Curran, C Scott, C Langer, R Komaki, J S Hauser, B Movsas, et al.: Long term ben-
efits is observed in a phase III comparison of sequential vs concurrent chemo-radiation
for patients with unresectable NSCLC: RTOG 9410. In: Proceeding of the American
Society of Clinical Oncology, 621a, 2003
[6] S Webb: Intensity Modulated Radiation Therapy. Institute of Physics, Dirac House,
Temple Back, Bristol BS1l 6BE, UKE, 2001.
[7] S Webb: Intensity modulated radiation therapy (imrt): a clinical reality for cancer
treatment. The British Journal of Radiology, 78: S64-S72, 2005.
[8] S Webb: The physical basis of imrt and inverse planning. The British Journal of Radi-
ology, 76: 678-689, 2003.
[9] W Schlegel, T Bortfeld, A L Grosu: New Technologies in Radiation Oncology, Springer-
Verlag Berlin Heidelberg, 2006.
[10] M van Herk: Errors and margins in radiotherapy, Seminars in Radiation Oncology,
14(1):52-64, 2004
[11] M. Guckenberger, T. Krieger, A. Richter, K. Baier, J. Wilbert, R. Sweeney, M. Flentje:
Potential of image-guidance, gating and real-time tracking to improve accuracy in pul-
monary stereotactic body radiotherapy. Radiotherapy and Oncology, 91:288-295, 2009.
[12] International Commission on Radiation Units and Measurements: Prescribing, record-
ing, and reporting photon beam therapy. ICRU Report 62, Bethesda, 1993.
77
[13] L Ekberg, O Holmberg: What margins should be added to the clinical target volume in
radiotherapy treatment planning for lung cancer. Radiotherapy and Oncology, 48:71-77,
1998.
[14] M van Herk, P Remeijer, C Rash, J V Lebesque: The probability of correct target dosage:
dose-population histograms for deriving treatment margins in radiotherapy, International
Journal of Radiation Oncology Biology and Physics, 47(45):1121-1135, 2000.
[15] R I Berbeco, H Mastafavi, G C Sharp, S B Jiang: Towards fluoroscopic respiratory
gating for lung tumours without radiopaque markers. Physics in Medicine and Biology,
50:4481-4490, 2005.
[16] J Meyer, A Richter, K Baier, J Wilbert, M Guckenberger, M Flentje: Tracking moving
objects with megavoltage portal imaging: A feasibility study. Medical Physics, 33:1275-
1280, 2006.
[17] M Aristophanous, J Rottmann, S Park, S Nishioka, H Shirato, R Berbeco: Image-guided
adaptive gating of lung cancer radiotherapy: a computer simulation study. Physics in
Medicine and Biology, 55:4321-4333, 2010.
[18] J P Keall, M Murphy, M van Herk, : The management of respiratory motion in
radiation oncology report of AAPM Task Group 76. Medical Physics, 33(10): 3874-3900,
2006.
[19] J Willner, K Baier, E Caragiani, A Tschammler, M Flentje: Dose, volume, and tumour
control prediction in primary radiotherapy of non-small-cell lung cancer. International
Journal of Radiation Oncology Biology and Physics, 52 (2):382-389, 2002.
[20] D Dosoretz, D Galmarini, J Rubenstein, M Katin, P Blitzer, S Salenius, R Dosani,
M Rashid, G Mestas, S Hannan: Local control in medically inoperable lung cancer:
and analysis of its importance in outcome and factors determining the probability of
tumour eradication. International Journal of Radiation Oncology Biology and Physics,
27(3):507-516, 1993.
[21] J Belberdos, JJ Sonke: State-of-the-art lung cancer radiation therapy, Expert Reviews
Anticancer Therapy, 9(10):1353-1363, 2009.
[22] L Fang, R Komaki, P Allen: Comparison of outcome for patients with medical inop-
erable Stage I non-small-cell lung cancer treated with two dimensional vs. three dimen-
sional radiotherapy. International Journal of Radiation Oncology Biology and Physics,
66(1):108-116, 2006.
[23] J P Keall, V R Kini, S S Vedam, R MohamPotential radiotherapy improvements with
respiratory gating. Australasian Physical and Engineering Sciences in Medicine, 25:1-6,
2002.
[24] H.D. Kubo, B.C. Hill: Respiration gated radiotherapy treatment: a technical study.
Physics in Medicine and Biology, 41:83-91, 1996.
78
[25] R W M Underberg, F J Largerwaard, B J Slotman, J P Cuijpers, S Senan: Benefits of
respiration-gated stereotactic radiotherapy for stage I lung cancer: An analysis of 4DCT
datasets. International Journal of Radiation Oncology Biology and Physics, 62:554-560,
2005.
[26] S Nishioka, T Nishioka, M Kawahara, S Tanaka, T Hiromura, K Tomita, H Shirato:
Exhale fluctuation in respiratory-gated radiotherapy of the lung: A pitfall of respiration
gating shown in a synchronized internal/external maker recording study. Radiotherapy
and Oncology, 86:69-76, 2008.
[27] Y Seppenwoolde, H Shirato, K Kitamura, S Shimizu, M van Herk, J V Lebesque,
K Miyasaka: Precise and real-time measurement of 3D tumour motion in lung due to
breathing and heartbeat, measured during radiotherapy. International Journal of Radia-
tion Oncology, Biology and Physics, 53(4):822-834, 2002.
[28] T J Nøttrup, S S Korreman, A N Pedersen, L R Aurup, H Nystro¨m, M Olsen, L Specht:
Intra- and interfraction breathing variations during curative radiotherapy for lung can-
cer. Radiotherapy and Oncology, 84:40-48, 2007.
[29] S.B. Jiang: Technical aspects of image-guided respiratory-gated radiation therapy. Med-
ical Dosimetry, 31:141-151, 2006.
[30] S S Korreman, T J Nøttrup, G F Persson, A N Pedersen, M Enmark, H Nystrom: The
role of image guidence in repiratory gated radiotherapy. Acta Oncologica, 47:1390-1396,
2008.
[31] M Guckenberger, A Kavanagh, S Webb, M Brada: A novel respiratory motion com-
pensation strategy combining gated beam delivery and mean target position concept -
A compromise between small safety margins and long duty cycles. Radiotherapy and
Oncology, 98:317-322, 2011.
[32] H Shirato, K Suzuki, G C Sharp, K Fujita, R Onimaru, M Fujino: Speed and ampli-
tude of lung tumor motion precisely detected in four-dimensional setup and in real-time
tumor tracking radiotherapy. International Juornal of Radiation Oncology, Biology and
Physics, 64(4):1229-1236, 2006.
[33] T Bortfeld, S B Jiang, A Rietzel: Effects of motion on total dose distributions, Seminars
in Radiation Oncology, 14(1):41-51, 2004.
[34] M Engelsman, G C Sharp, T Bortfeld, R Onimaru, H Shirato: How much margin
reduction is possible through gating or breath hold?. Physics in Medicine and Biology,
50:477-490, 2005.
[35] M Engelsman, E M F Damen, K De Jaeger, K M van Ingen, B J Mijnheer: The effects
of breathing and set-up errors on cumulative dose to a lung tumour, Radiotherapy and
Oncology, 60:95-105, 2001.
79
[36] J Meyer,K Baier, J Wilbert, M Guckenberger, A Richter, M Flentje: Three-dimensional
spatial modelling of the correlation between abdominal motion and lung tumour motion
with breathing. Acta Oncologica, 45:923-934, 2006.
[37] L Ma, C Herrmann, K Schilling: Modeling and prediction of lung tumor motion for
robotic assited radiotherapy. 2007 IEEE/RSJ International Conference on Intelligent
Robots and Systems (IROS 2007), San Diego, CA, 189-194, 2007 (unpublished).
[38] J J Sonke, R T Lebesque, M van Herk: Variability of four-dimentional computed
tomography patient models, International Journal of of Radiation Oncology Biology and
Physics, 70:590-598, 2008.
[39] A Richter, J Wilbert, K Baier, M Flentje, M Guckenberger: Feasibility study for mark-
erless tracking of lung tumour in stereotactic body radiotherapy. International Journal
of Radiation Oncology Biology and Physics, 78:618-627, 2010.
[40] J W H Wolthaus, J J Sonke, M van Herk, J S A Belberdos, M M G Rossi, J V Lebesque,
E M F Damen: Comparison of different strategies to use for four-dimensional computed
tomography in treatment planning for lung cancer patients, Physics in Medicine and
Biology, 70(4):1229-1238, 2008
[41] R D Timmerman, L Xing: Image-Guided and Adaptive Radiation Therapy, Lippincott
Williams and Wilkins, 2009.
[42] J Wilbert, J Meyer, K Baier, M Guckenberger, K Herrmann, R Hess, C Janka, L Ma,
T Mersebach, A Richter, M Roth, K Schilling, M Flentje: Tumor tracking and motion
compensation with an adaptive tumor tracking system (ATTS): System description and
prototype testing. Medical Physics, 35:3911-3921, 2008.
[43] M van Herk, M Witte, J van der Geer: Biological and physical fractionation effects of
random geometrical errors, International Journal of Radiation Oncology Biology and
Physics, 57:1460-1471, 2003.
[44] H Shirato, S Shimizu, T Kunieda, K Kitamura, M Van Herk, K Kagel, T Nishioka,
S Hashimoto: Physical aspects of real-time tumour tracking system for gated radiother-
apy. International Juornal of Radiation Oncology, Biology and Physics, 48(4):1187-1195,
2005.
[45] S S Korreman, T J Nøttrup, A Boyer: Respiratory gated beam delivery cannot facilitate
margin reduction, unless combined with respiratory correlated image guidance. Radio-
therapy and Oncology, 86:61-68, 2008.
[46] R I Berbeco, S Nishioka, H Shirato, G T B Chen, S B Jiang: Residual motion of lung
tumours in gated radiotherapy with external respiratory surrogates. Physics in Medicine
and Biology, 50:3655-3667, 2005.
[47] H Wu, Q Zhao, R I Berbeco, S Nishioka, H Shirato, S B Jiang: Gating based on
internal/external signals with dynamic correlation updates. Physics in Medicine and
Biology, 53:7137-7150, 2008.
80
[48] X A Li, P J Keall, C G Orton: Respiratory gating for radiation therapy is not ready for
prime time. Medical Physics, 34:867-870, 2007.
[49] M J Murphy: Tracking moving organs in real time. Seminars in Radiation Oncology,
14(1): 91-100, 2004.
[50] K Baier, J Meyer: Fast image acquisition and processing on a TV camera-based portal
imaging system. Medical Physics, 15:122-125, 2005.
[51] X A Li, C Stepaniak, E Gore: Technical and dosimetric aspects of respiratory gating
using a pressure-sensor motion monitoring system. Medical Physics, 31(1): 145-154,
2006.
[52] T Lin, L I Cervino, X. Tang, N Vasconcelos, S B Jiang: Fluoroscopic tumor tracking
for image-guided lung cancer radiotherapy. Physics in Medicine and Biology, 54:981-992,
2009.
[53] R Berbeco, S Nishioka, H Shirato, G Chen, S Jiang: Clinical feasibility of using an
EPID in cine mode for image-guided verification of stereotactic body radiotherapy. In-
ternational Journal of Radiation Oncology Biology and Physics, 69:258-266, 2007.
[54] D Ionascu, S Jiang, S Nishioka, H Shirato, R Berbeco: Internal-external correlation in-
vestigations of respiratory induced motion of lung tumors. Medical Physics, 34(10):3893-
3903, 2007.
[55] C Grohman, R Werner, D Alberts, F Cremers: Analysis of dose shifts induced
by organ movements during treatment with TomoTherapy using a motion phantom
and GafChromic EBT films. University Medical Centre Hamburg-Eppendorf, World-
Congress UKE, Germany, 2009.
[56] C Nelson, G Starkschal, P Balter, R Morice, C Stevens, J Chang: Assessment of lung
tumour motion and setup uncertainties using implanted fiducials. International Journal
of Radiation Oncology Biology and Physics, 67:915-923, 2007.
[57] J W H Wolthaus, C Schneider, J J Sonke, M van Herk, J S Belderbos, M M Rossi,
R T Lebesque, E M Damen: Mid-Ventilation CT scan construction from four-
dimensional respiratory-correlated CT scans for radiotherapy planning of lung cancer
patients, Physics in Medicine and Biology, 65(5):1560-1571, 2006.
[58] Y Tsunashima, T Sakae, Y Shioyama, K Kagei, T Terunuma, A Nohtomi, Y Akine:
Correlation between the respiratory waveform measured using a respiratory sensor and
3D tumour motion in gated radiotherapy. International Journal of Radiation Oncology
Biology and Physics, 60(3):951-958, 2004.
[59] R Berbeco, T Neicu, E Rietzel, G Chen, S Jiang: A Technique for respiratory-gated
radiotherapy treatment verification with an EPID in cine mode. Physics in Medicine
and Biology, 50(16):3669-3679, 2005.
[60] P L Wilson, J Meyer: A spring-dashpot system for modelling lung tumour motion in
radiotherapy. Computational and Mathematical Methods in Medicine, :1-14, 2009.
81
